Drug, bio-affecting and body treating compositions inventions 03/07

20070072790 - Antitumor agents: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070072791 - Glycogen synthase kinase-3 inhibitors: Peptide inhibitors of glycogen synthase kinase-3 (GSK-3) having an amino acid sequence motif of XZXXXS(p)X, wherein S(p)=phosphorylated serine or phosphorylated threonine, X=any amino acid, and Z=any amino acid except serine or threonine. These inhibitors, which are about 7 to 20 amino acids long, are specific for GSK-3 and strongly inhibit... Agent: Martin D. Moynihan Prtsi, Inc.

20070072793 - Histone hyperacetylating agents for promoting wound healing and preventing scar formation: A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth... Agent: Fish & Richardson PC

20070072792 - Macrocyclic lactams and pharmaceutical use thereof: wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use... Agent: Novartis Corporate Intellectual Property

20070072799 - Acid-labile subunit (als) of insulin-like growth factor binding protein complex: e

20070072803 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Cozen O'connor, P.C.

20070072804 - Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level: The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the... Agent: Cozen O'connor, P.C.

20070072800 - Conjugates for cancer therapy and diagnosis: The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as... Agent: Winston & Strawn LLP Patent Department

20070072797 - Epitopes: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.... Agent: Davis Wright Tremaine, LLP

20070072798 - Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same: This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in human proteolytical system such as serine and cysteine proteases and their inhibitors and pharmaceutical agents and other therapies affecting these. This invention discloses methods for the treatment and prevention of cardiovascular diseases such... Agent: Birch Stewart Kolasch & Birch

20070072801 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070072794 - Novel genes and proteins encoded thereby: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, pharmaceutical compositions and the formulation of such compositions comprising said nucleic acids or proteins expressed therefrom,... Agent: Olson & Hierl, Ltd.

20070072796 - Oligonucleotide analogues incorporating 5-aza-cytosine therein: Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2′-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible... Agent: Wilson Sonsini Goodrich & Rosati

20070072802 - Peptide nucleic acid based guanidinium compounds: Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport of a polymer backbone across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The polymer backbone may include peptide nucleic acid monomer units.... Agent: Knobbe Martens Olson & Bear LLP

20070072795 - Treatment of neurodegenerative disorders: A method of treating neurodegenerative disorders of the brain and spinal cord using a novel ethropoietic agent.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070072805 - Peptides and their use for the treatment of hiv infections: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is... Agent: Jacobson Holman PLLC

20070072806 - Inhibitor of the folding of the hiv-1-protease as antiviral agent: The invention relates to the design of inhibitors of the HIV-1-PR homodimer which do not create resistance, by blocking the folding of single monomers with the help of peptides which attach to highly-conserved sites of the monomers.... Agent: Shoemaker And Mattare, Ltd

20070072807 - Method of screening compounds: A method of screening compounds to identify those compounds which inhibit the Asp 1 mediated cleavage of a polypeptide or protein substrate, the method comprising: providing a reaction system comprising Asp 1 and substrate; and measuring the extent of cleavage of the substrate in the presence of test compound as... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070072808 - Antimicrobial and anticancer lipopeptides: The invention provides lipophilic conjugates comprising a peptide coupled to a fatty add, the peptide comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment... Agent: Heslin Rothenberg Farley & Mesiti PC

20070072809 - Antiviral compounds: The invention is related to HCV inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Intellectual Property Department Gilead Sciences, Inc.

20070072810 - Agent for treating diabetes: An agent for treating diabetes with sulfonylurea secondary failure which comprises a dipeptidyl peptidase IV inhibitor. The agent of the present invention is an agent for treating diabetes with sulfonylurea secondary failure showing excellent insulin-secreting and hypoglycemic effects on even diabetic patients on whom a sulfonylurea compound or a fast-acting... Agent: Foley And Lardner LLP Suite 500

20070072811 - Bifunctional heterocyclic compounds and methods of making and using the same: The invention provides a family of bifunctional heterocyclic compounds useful as antiinfective, anti-proliferative, anti-inflammatory, and prokinetic agents. The invention also provides methods of making the bifunctional heterocyclic compounds, and methods of using such compounds as anti-infective, anti-proliferative agents, anti-inflammatory, and/or prokinetic agents.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070072813 - Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives: The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for preventing or treating of complications of diabetes mellitus, for reducing the weight, for preventing or treating... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072812 - Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones: e

20070072814 - Method and means of modulating lipid metabolism: The present invention relates to modulation of lipid metabolism, in particular reductions in the levels of total cholesterol and apo-lipoprotein, of an individual. This modulation is achieved by combined administration of both anti-microbial and metal-chelator compounds. Various therapeutic applications of this lipid modulation are provided.... Agent: Nixon & Vanderhye, PC

20070072819 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070072820 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070072821 - Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In... Agent: Celera Diagnostics, LLC

20070072815 - Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration: Methods, kits and cell lines are presented for effecting oligonucleotide-directed genetic alteration at a specific locus in a target DNA molecule in a population of cells at increased efficiency.... Agent: Basil S. Krikelis Citizens Bank Center

20070072816 - Methods for inhibiting angiogenesis: Methods for inhibiting angiogenesis using gene therapy are disclosed. Genes encoding PLGF or VEGF-B are delivered to cells e.g., tumor cells, which express VEGF, such that heterodimers of PLGF/VEGF and/or VEGF-B/VEGF are formed within the cells, preferably at a greater ratio than homodimers of VEGF/VEGF. The heterodimers have reduced angiogenic... Agent: Lahive & Cockfield, LLP

20070072817 - Methods for reducing blood pressure: The present invention relates to methods and agents for reducing blood pressure. Methods and agents for reducing diastolic blood pressure, for reducing systolic blood pressure, and for reducing mean arterial pressure are also provided.... Agent: Fibrogen, Inc. Intellectual Property Department

20070072818 - Regulation of angiogenesis with zinc finger proteins: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by... Agent: Townsend And Townsend And Crew, LLP

20070072823 - Sirna targeting survivin: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.... Agent: Kalow & Springut LLP

20070072822 - Stat3 agonists and antagonists and therapeutic uses thereof: The present invention relates to methods for modulating, i.e., agonizing or antagonizing, Stat3 (Signal Transducer and Activator of Transcription3) signaling activity for use in gene therapy. Inhibition and/or activation of Stat3 signaling is an effective approach to modulate angiogenesis and the immune response for treatment and/or prevention of inflammation, infection,... Agent: Fish & Richardson P.C.

20070072826 - Compositions and methods for modulation of vascular structure and/or function: The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as... Agent: Jones Day

20070072824 - Methods of reducing the severity of mucositis: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.... Agent: Clark & Elbing LLP

20070072825 - N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof: The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds, compositions comprising an effective amount of an N-Benzyl-Substituted Pyridyl Porphyrin Compound and methods for treating or preventing injury due to exposure to a reactive species, erectile dysfunction, urinary incontinence, lung disease, hyperoxia, neurodegenerative disease, liver disease, myocardial damage during cardioplegia, an... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070072827 - Insecticide formulation: The present invention provides a new insecticide formulation based on cyclodextrin characterised in that the active substance (insecticide and/or insect growth regulator), and a compound synergistic with the active substance, are complexed simultaneously with cyclodextrin. The formulation presents as a solid or as a solid/oil composition, and is soluble or... Agent: Jay S. Cinamon Abelman, Frayne And Schwab

20070072828 - Bile preparations for colorectal disorders: The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or... Agent: Baker Botts L.L.P. Patent Department

20070072829 - Fungicidal composition comprising a pyridylmethylbenzamide derivative and a sulfamide derivative: A composition comprising at least a pyridylmethylbenzamide derivative of general formula (I) and N-dichlorofluoromethylthio-N′,N′-dimethyl-N-p-tolylsulfarnide; in an (a)/(b) weight ratio of from 0.01 to 10. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the phytopathogenic fungi of crops by using this composition.... Agent: Ostrolenk Faber Gerb & Soffen

20070072830 - Methods for treating diabetes: The invention relates to compositions of Glu-boroPro and methods of use thereof in the prevention or management of type 2 diabetes.... Agent: Wolf Greenfield & Sacks, PC

20070072831 - Integrase inhibitor compounds: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.... Agent: Intellectual Property Department Gilead Sciences, Inc.

20070072832 - Novel benzopyran derivatives as potassium channel openers: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20070072833 - Survivin inhibitors: Compounds that inhibit survivin, compositions containing the compounds and methods of treating diseases in which survivin is unregulated or overexpressed are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070072834 - 13-substituted methacycline compounds: 13-substituted methacycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 13-substituted methacycline compounds are described.... Agent: Lahive & Cockfield, LLP

20070072835 - Method of preparing and use of prodrugs of betulinic acid derivatives: A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betulinic acid or a betulinic acid derivative is administered in a prodrug form to release betulinic acid... Agent: Marshall, Gerstein & Borun LLP

20070072836 - Solid peroral contraceptive preparations: The solid peroral contraceptive contains an effective ingredient combination of dienogest in a daily dosage of equal to or less than 2.0 mg and ethinyl estradiol in a daily dosage of less than 0.03 mg together with one or more pharmaceutically acceptable carriers. The dienogest is released in two stages,... Agent: Striker, Striker & Stenby

20070072837 - Phenylalkynes: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20070072838 - High-purity texaphyrin metal complexes: Disclosed herein are the methods and compositions for the improved synthesis of texaphyrin metal complexes. The improved synthesis results in high-purity compositions of texaphyrin metal complexes in which more than about 98% of the texaphyrin metal complexes in the composition have the same structure and/or the same molecular weight. Further... Agent: Wilson Sonsini Goodrich & Rosati

20070072839 - Leukemia treatment method and composition: A method of inducing high anti-leukemia activity responsive to the combination of hydroxamic acid analogue histone deacetylase inhibitors and PKC412 against human acute leukemia characterized as expressing phosphorylated (p)FLT3 kinase by a novel flow cytometry-based assay.... Agent: Smith Hopen, Pa

20070072840 - Polymorphic forms of quetiapine: The invention relates to processes for the preparation of polymorphic forms of salts of quetiapine. More particularly, it relates to the preparation of polymorphic forms of quetiapine hydrochloride designated as Form A, B, and C. The invention also relates to pharmaceutical compositions that include the Form A, Form B, and... Agent: Ranbaxy Inc.

20070072841 - Therapeutic compounds: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.... Agent: Notaro And Michalos

20070072842 - 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors: e

20070072843 - Pyridyl substituted xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Proskauer Rose LLP

20070072844 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto: e

20070072845 - Process for the preparation of olanzapine form 1 useful as antipsychotic drug: This invention provides an improved process for the preparation of Olanzapine Form (I). Olanzapine, which is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazapine. More specially, the invention provides insitu improved process for the direct preparation of crystalline form of Olanzapine Form (I). The present invention also provides high pure Olanzapine Form I with single individual impurity... Agent: Moore & Van Allen PLLC

20070072846 - Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto: Disclosed are compounds of Formula (I) wherein X, Y, Ri-R7,T1, T2, Z, and p are as described herein; a pharmaceutical composition comprising a compound of Formula (I) and a carrier; a method of inhibiting growth of a cell, which method comprises administering in an amount effective to inhibit growth a... Agent: Leydig, Voit & Mayer, Ltd.

20070072847 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3 and R4 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072848 - Combinations of at1-antagonists, amiloride or triamterine, and a diuretic: e

20070072849 - Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods: Non-steroidal tricyclic quinolinone and tricyclic quinoline compounds and compositions that are agonists, partial agonists and/or antagonists for androgen receptors (AR), their preparation and their uses are described.... Agent: Fish & Richardson, PC

20070072850 - Pesticides: n

20070072851 - Pyrazolopyridine and pyrazolopyrimidine compounds:

20070072852 - Heterocyclic aspartyl protease inhibitors: and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072853 - Benzimidazole derivatives compositions containing them, preparation thereof and uses thereof: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4, n and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070072854 - Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive: m

20070072857 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto:

20070072856 - Lpaat-beta inhibitors and uses thereof: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.... Agent: Seed Intellectual Property Law Group PLLC

20070072855 - Pyrazole compounds as hsp90 inhibitors for the treatment of cancer: Compounds of formula (I) are inhibitors of HSP90 activity, and useful in the treatment of proliferative disease such as cancers: wherein R1, R2 and R3 are as defined in the specification, and X is —OR4 or —NR4R5 wherein R4 and R5 independently represent hydrogen or optionally substituted C1-C6 alkyl, or... Agent: Banner & Witcoff

20070072858 - Process for the stereoselective preparation of (-)-halofenate and derivatives thereof: each R2 is a member independently selected from the group consisting of (C1-C4)alkyl, halo, (C1-C4)haloalkyl, amino, (C1-C4)aminoalkyl, amido, (C1-C4)amidoalkyl, (C1-C4)sulfonylalkyl, (C1-C4)sulfamylalkyl, (C1-C4)alkoxy, (C1-C4)heteroalkyl, carboxy and nitro; the subscript n is 1 when R1 has the formula (a) or (b) and 2 when R1 has the formula (c) or (d); the... Agent: Townsend And Townsend And Crew, LLP

20070072859 - Pharmaceutical compounds: The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from —O— and —S—; X is selected from C1-C8 alkyl, C2-C8 alkenyl, and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each... Agent: Eli Lilly & Company

20070072860 - Apoptosis promoters: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent: Robert Deberardine Abbott Laboratories

20070072861 - Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders: This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.... Agent: Pharmacia Corporation Global Patent Department

20070072862 - Bis-aryl amide compounds and methods of use: wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions... Agent: Amgen Inc.

20070072864 - Fused tricyclic mgiur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072863 - Fused tricyclic mglur1 antagonists as therapeutic agents: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072865 - Bicyclic piperazine compound and use thereof: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X... Agent: Takeda Pharmaceuticals North America, Inc Intellectual Property Department

20070072866 - 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments: The present invention relates to kinase inhibitor compounds and derivatives thereof as well as compositions comprising them for the treatment of neurological disorders such as Alzheimers' disease, Parkinsons' disease, obesity, hypertension and the like. These pyridazinone derivatives particularly inhibit the metabolic activity of glycogen synthase kinase —3β (GSK-3β) which is... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070072867 - 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5amine: e

20070072868 - Novel synthesis of gatifloxacin: Provided are a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.... Agent: Kenyon & Kenyon LLP

20070072869 - Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders: o

20070072870 - Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition:

20070072871 - Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors: The present invention provides a compound of formula (I):... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070072872 - Treating sexual desire disorders with flibanserin: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072874 - Aminoheteroaryl compounds as protein kinase inhibitors: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET.... Agent: Foley And Lardner LLP Suite 500

20070072873 - Novel thiophene derivatives which are hm74a agonists: i

20070072875 - Anti-inflammatory compositions and methods of use: The present invention is directed to pharmaceutical compositions containing active compounds, which inhibit the activity of the chemokines, MIP-1α and RANTES. It also is directed to methods of treating inflammatory and immunoregulatory disorders and diseases using these pharmaceutical compositions.... Agent: Brinks Hofer Gilson & Lione

20070072877 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection: The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070072878 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection: The present invention relates to novel compounds and methods that are useful in treating members of the Flaviviridae family of viruses. Compounds of the present invention will have a structure according to Formulas (I)-(VI) as recited throughout the application.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070072876 - Novel pyrimidine carboxamides: The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the... Agent: Oliff & Berridge, PLC

20070072879 - Novel compounds as metabotropic glutamate receptor antagonists: wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070072880 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072881 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072882 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070072883 - Fungicidal mixtures:

20070072884 - Quinolin-isoquinolin-and quinazolin-oxyalkylamides and their use as fungicides: in which the optionally substituted phenyl and thienyl rings of the R5 values are optionally substituted with one, two or three substituents selected from halo, hydroxy, mercapto, C1-4 alkyl, C2-4, alkenyl, C2-4 alkynyl, C1-4 alkoxy, C2-4 alkenyloxy, C2-4 alkynyloxy, halo (C1-4)alkyl, halo(C1-4)alkoxy, C1-4 alkylthio, halo(C1-4)alkylthio, hydroxy(C1-4)alkyl, C1-4 alkoxy(C1-4)alkyl, C3-6 cycloalkyl,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070072885 - Bicyclic derivatives for the treatment of abnormal cell growth: and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R5, and X are as defined herein, and wherein the compound of formula 1 optionally further comprises a hydroxy substituent, an O-glucuronic acid, or an N−>O (N-oxide) moiety. The invention also relates to methods of treating abnormal... Agent: Pfizer Inc

20070072886 - Method of treating movement disorders using barbituric acid derivatives: d

20070072888 - Indol-3-yl-carbonyl-azaspiro derivatives: wherein the azaspiro-head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070072887 - Spirofuropyridine aryl derivatives: and pharmaceutically-acceptable salts thereof, wherein A, B, and R1 are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070072889 - Hydrocodone polymorphs: Hydrocodone bitartrate forms are disclosed which are useful as analgesic agents either in combination with or as replacements for hydrocodone bitartrate.... Agent: Philip S. Johnson Johnson & Johnson

20070072890 - Novel crystal forms of irinotecan hydrochloride: The present invention provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating metastatic carcinoma of the colon or rectum using same.... Agent: Cohen, Pontani, Lieberman & Pavane

20070072892 - Amino-aza-adamantane derivatives and methods of use: The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Radiolabelled compounds useful for evaluating the binding affinity to α7 nicotinic acetylcholine receptors also are described.... Agent: Robert Deberardine Abbott Laboratories

20070072891 - Method for the protection against the risk of cardiac disorders comprising administration of tiotropium salts: The instant invention relates to a method for protecting a patient against the risk of cardiac disorders, comprising the administration of a therapeutically effective amount of a tiotropium salt.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070072893 - Substituted imidazo ring systems and methods: Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, inter-mediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20070072894 - Synthesis of pyrroloquinoline quinone (pqq): The invention relates to a novel nine step process for synthesizing PQQ (methoxatin). This process is efficient and reliably provides PQQ in excellent purity and high yield.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070072896 - Inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation: The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070072897 - Phenylaminopropanol derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP

20070072895 - Polymorphs of 1-cyclopropyl-7-([s,s])-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro -8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof: the preparation thereof, and their pharmaceutical compositions are described. These crystalline forms, which are characterized by greater stability and ease of preparation and of formulation, can be produced by industrially applicable methods which comprises the steps of: a) suspending 1-cyclopropyl-7-([S,S])-2,8-diazadicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride in a solvent selected from an alcohol... Agent: Nixon & Vanderhye, PC

20070072899 - Method for treating drug and behavioral addictions: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.... Agent: Robins & Pasternak

20070072898 - Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof: A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.... Agent: Sughrue Mion, PLLC

20070072901 - 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5: p

20070072900 - P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same: The bioavailability of an anticancer agent is enhanced when the anticancer agent is administered together with a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Agent: Sughrue Mion, PLLC

20070072902 - Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses: The invention encompasses novel compounds, pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds, and methods of using these compounds and compositions in mammals for treatment or prevention of diseases associated with PDE4.... Agent: Jones Day

20070072903 - Altering the concentration of intracellular agents by p2x7 receptor modulation: Disclosed is an in vitro method of increasing the effective intracellular concentration of a therapeutic molecule within a cell expressing a P2X7 receptor, the method comprising the step of contacting the cell with the therapeutic molecule and with a substance which stimulates the P2X7 receptor.... Agent: Morgan Lewis & Bockius LLP

20070072904 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds and compounds selective for any one or any two of PPARα, PPARα and PPARδ. Also described are methods of use of the compounds in treating various diseases.... Agent: Foley & Lardner LLP

20070072905 - Novel process for preparing dopenzil and its derivatives: A process for producing a Donepezil derivative represented by the formula (I), wherein R1, R2, R3, and R4 each independently represents H, F, an alkyl having from 1 to 4 carbon atoms, or an alkoxy having from 1 to 4 carbon atoms; R5 represents a phenyl or a substituted phenyl;... Agent: Matthias Scholl

20070072908 - Heterocyclic compounds: p

20070072909 - Methods for making 4-tetrazolyl-4-phenylpiperidine compounds: where Ar1 is —C3-C8 cycloalkyl, phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Ar2 is phenyl, naphthyl, anthryl, phenanthryl or -(5-7-membered) heteroaryl, each being unsubstituted or substituted with one or more R2 groups; Z1 and Z2 are each independently a... Agent: Jones Day

20070072906 - Pyrrole compounds: e

20070072907 - Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070072910 - Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans: The present invention is directed to compositions and method to lower the plasma concentration of a low density lipoprotein in a human. One aspect is the invention is directed to compositions comprising at least one pharmaceutically acceptable L-carnitine compound and at least one pharmaceutically acceptable niacin compound, in such amount... Agent: Knobbe Martens Olson & Bear LLP

20070072911 - Indoles and azaindoles as antiviral agents: The present invention relates to indoles and azaindoles of formula (1): wherein X1, X2, X3, X4, A1, Ar1, Ar, n, p and q are as defined herein and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C virus infections.... Agent: Merck And Co., Inc

20070072912 - Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants: Compounds of the formula (I) and their pharmaceutically acceptable or technically applicable acid salts—where in the formula R1 represents hydrogen, C(1-4)alkyl or C(1-4)alkoxy R2 represents hydrogen, C(1-4)alkyl, carboxyl, C(1-4)alkoxycarbonyl, carboxamido, aryl or hetero-aryl R3 represents hydrogen, C(1-4)alkyl, aryl-methylene, or aryl, Y is a valency bond, a straight or branched chain... Agent: Davis Wright Tremaine LLP

20070072913 - New crystalline form of omeprazole: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation... Agent: White & Case LLP Patent Department

20070072914 - N-(pyridin-2-yl)-sulfonamide derivatives: The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds described herein, their pharmaceutically acceptable salts, hydrates and solvates, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme... Agent: Pfizer Inc

20070072915 - Novel phenoxyacetamide derivative and use thereof for preparation of diphenylamines: The present invention relates to novel phenoxyacetamide derivatives, to a process for the preparation thereof and to the use thereof for the preparation of diphenylamines.... Agent: Millen, White, Zelano & Branigan, P.C.

20070072916 - Amino ceramide-like compounds and therapeutic methods of use: Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070072917 - Substituted 2-aminotetralin for the treatment of depression: The invention relates to the use of a compound of general formula (I) and the pharmaceutically acceptable salts, racemates or pure enantiomers thereof for the production of a medicament used to treat depression. The substituents are defined as in the description.... Agent: Harness, Dickey, & Pierce, P.l.c

20070072918 - Benzothiadiazolylphenylalkylamine derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP

20070072920 - Phenylethylamine analogs and their use for treating glaucoma: Phenylethylamine analogs useful for treating glaucoma are disclosed.... Agent: Alcon Research, Ltd. Patrick M. Ryan Tb4-8

20070072919 - Process for the preparation of compounds having an ace inhibitory action: e

20070072921 - Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide: A stable crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide is described. This crystal structure, designated Form B, is more stable, has favorable handling properties and is characterized by its melting point, x-ray and other physical characterizations.... Agent: Pharmacia Corporation Global Patent Department

20070072922 - 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline: An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070072923 - Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde: The present invention provides a process for producing 2′-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde which comprises reacting 2′-cyanobiphenyl-4-carbaldehyde with a salt of azide; a process for producing a highly pure crystal of 2′-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde which comprises reacting 2′-cyanobiphenyl-4-carbaldehyde with a salt of azide, obtaining a crystal of 2′-(1H-tetrazol-5-yl)biphenyl-4-carbaldehyde, dissolving said crystal obtained and recrystallizing a highly... Agent: Foley And Lardner LLP Suite 500

20070072924 - Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present... Agent: Cozen O'connor, P.C.

20070072925 - Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase: s

20070072926 - 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds: where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as... Agent: Allergan, Inc.

20070072927 - Nutritional supplement for increased energy and stamina: In a method of treating hypertension in individuals suffering therefrom, the method includes administering to said individuals an effective amount of carnitine and an effective amount of lipoic acid. A method of treating hypertension in individuals suffering therefrom includes administering twice a day a combination of 500 mg carnitine, 200... Agent: The Luther Law Firm

20070072928 - Substituted propylamine derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP

20070072929 - Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines: The present application describes nitroimidazolic derivative compounds with antibacterial and/or antiprotozoal activity, which are potent urease inhibitors. It also describes the process for preparing those compounds and their use in pharmaceutical compositions and medicines.... Agent: Birch Stewart Kolasch & Birch

20070072930 - N-substituted pyrazolyl carboxanilides: e

20070072931 - Pharmaceutical composition and a method for treatment of prostate cancer: The present invention is directed to pharmaceutical compositions and methods for treatment of prostate cancer in a subject. The pharmaceutical composition includes a therapeutically effective amount of compound mahanine, or derivatives, or analogues, or pharmaceutically acceptable salt thereof. The present invention is further directed to a method of isolating compound... Agent: Brinks Hofer Gilson & Lione

20070072934 - Alkoxy indolinone based protein kinase inhibitors: Alkoxy indolinone based acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.... Agent: The Scripps Research Institute

20070072933 - Delivery of an ocular agent: A method to ameliorate age related macular degeneration or another disease of fluid leakage from new ocular blood vessels to a surrounding area, by administering sunitinib maleate. In one embodiment, sunitinib maleate is administered without photodynamic or laser coagulation therapy. In one embodiment, sunitinib maleate is administered in conjunction with... Agent: Wood, Herron & Evans, LLP

20070072932 - Use of tyrosine kinase inhibitor to treat diabetes: The invention relates to the use of a c-Abl-, PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1 -ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.... Agent: Novartis Corporate Intellectual Property

20070072935 - Catalytic antioxidants and methods of use: The invention provides small molecules that act as catalytic antioxidants and methods of use thereof. The compounds can repeatedly bind and destroy reactive oxygen species by serving as substates for enzymes of the methionine sulfoxide reductase (Msr) class. Some embodiments of the catalytic antioxidant compounds are derived from drugs with... Agent: Akerman Senterfitt

20070072936 - Androgen modulators: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Warner-lambert Company

20070072937 - Pharmaceutical composition comprising alpha-lipoic acid for inflammatory diseases: The present invention relates to a pharmaceutical composition containing α-lipoic acid (LA) as an active ingredient. α-lipoic acid is an inhibitor of fractalkine expression, and exhibits effects of alleviating inflammation due to endotoxemia by decreasing expression of fractalkine and attachment of endothelial cells to monocytes in endothelial cells of an... Agent: Birch Stewart Kolasch & Birch

20070072939 - Cannabinoid active pharmaceutical ingredient for improved dosage forms: Pharmaceutical compositions comprising the cannabinoid active pharmaceutical ingredient, crystalline trans-(±)-Δ9-tetrahydrocannabinol, and formulations thereof are disclosed. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of crystalline trans-(±)-Δ9-tetrahydrocannabinol. In specific embodiments, the crystalline trans-(±)-Δ9-tetrahydrocannabinol... Agent: Jones Day

20070072938 - Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting: In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-tetrahydrocannabinol and methods of administering such compositions prior to the administration of chemotherapy to prevent or reduce the development of delayed chemotherapy-induced nausea and vomiting.... Agent: Mayer, Brown, Rowe & Maw LLP

20070072940 - Use of quinol derivatives thereof for cosmetic, dietary supplement or pharmaceutical compositions and compositions thereby obtained.: The present invention relates to a cosmetic, dietary supplement, or pharmaceutical composition for oral ingestion or topical application to the skin comprising effective amounts of a tocopherol quinone, tocopherol quinol, plastoquinol, menaquinol, or phylloquinol compound, or any combination thereof as a method for preventing free radical oxidation or preventing or... Agent: Sal Abraham

20070072941 - Suppression and prevention of tumors: Combinations of betaine and vitamin C are used to suppress or prevent malignant tumors, e.g., by combining the two ingredients in an aqueous liquid such as grape juice and the ingredients are usefully provided in containers with instructions for use, especially with support of tests demonstrating the effectiveness of the... Agent: Robert B. Aylor

20070072942 - Statin derivatives: Statin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for treating and/or preventing several diseases, in particular coronary syndromes, neurodegenerative disorders as well as for reducing cholesterol levels.... Agent: Arent Fox PLLC

20070072943 - Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a... Agent: Morrison & Foerster LLP

20070072944 - Amidoacetonitrile derivatives: The invention relates to compounds of the general formula (I) wherein X, Y and W have the significances given in claim 1 and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites in and on warm-blooded animals.... Agent: Novartis Corporate Intellectual Property

20070072945 - Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake: The present invention relates to sulphur-containing oils, their preparation, and their use in controlling/killing plant pathogens and stimulating a plant's uptake of essential elements from the soil and to act as a soil pH adjuster.... Agent: Ranbaxy Inc.

20070072946 - Milnacipran for the long-term treatment of fibromyalgia syndrome: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with... Agent: Darby & Darby P.C.

20070072947 - Use of deoxypeganine for treating schizophrenic psychoses: Deoxypeganine in the form of a free base or in the form of an acid addition salt, or a derivative of deoxypeganine as long as the derivative is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase. The deoxypeganine can be used for producing a medicament for treating a schizophrenic... Agent: D. Peter Hochberg Co. L.p.a.

20070072948 - Composition comprising long-chain alcohols for suppressing concentrations of c-reactive protein (crp) in human blood: Long-chain alcohols based on montan wax alcohols, beeswax alcohols and Guerbet alcohols can advantageously be used in a composition for efficiently lowering elevated CRP levels. It is surprisingly also possible thereby to influence beneficially pathophysiological processes, in particular CHD, stroke or complications of rheumatoid diseases which are associated with elevated... Agent: Clariant Corporation Intellectual Property Department

20070066512 - Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels: Methods of treating, preventing and/or managing disorders associated with low plasma leptin levels are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.... Agent: Jones Day

20070066513 - Substituted metal-phthalocyanines, their preparation and the use thereof: The present invention is directed to metal-phthalocyanines of general formula (I) to the corresponding conjugates, the processes for their preparation and use in the photodynamic therapy of microbial infections (viral, bacterial and mycotic), tumor, pre-cancerous and proliferative pathologies and/or in the diagnosis, as well as for blood and blood derivatives... Agent: Nixon Peabody, LLP

20070066514 - Regulation of mineral and skeletal metabolism: A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting... Agent: Bozicevic, Field & Francis LLP

20070066515 - Novel glycoprotein and pharmaceutical composition containing the same: A novel glycoprotein having (a) a molecular weight of approximately 60 kDa and (b) a ratio of a carbohydrate content to a protein content of 16.4:1.0 (carbohydrate: protein) is disclosed. The glycoprotein can be prepared by (1) extracting Tricholoma matsutake with an alkaline solution or hot water, (2) adsorbing the... Agent: Reed Smith LLP

20070066516 - Compounds comprising cyclized somatostatin receptor binding peptides: The present invention concerns compounds comprising novel cyclized peptides with increased selectivity towards binding to the somatostatin receptor 5 (SSTR5) its production and use in the diagnosis and treatment of somatostatin-responsive diseases or diseases characterized by up-regulation of somatostatin receptors, in particular proliferative diseases.... Agent: Millen, White, Zelano & Branigan, P.C.

20070066517 - Composition and method for treating graft-versus-host disease: Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute... Agent: Blank Rome LLP

20070066523 - chemokine analogs for the treatment of human diseases: The present invention is concerned with chemokine analogs, including IL-8 analogs, IP-10 analogs, MIP-1α analogs, RANTES analogs, I-309 analogs, MCP-1 analogs, and CCL28 analogs, that are useful for the treatment of a variety of diseases and disorders, and as an adjunct to the treatment of a variety of diseases and... Agent: Perkins Coie LLP

20070066529 - Acaricidal compositions and methods of use thereof: A method of controlling acarine pests comprises applying to the locus of the acarine pests, an isolated polypeptide toxin, wherein the polypeptide toxin has acaricidal activity. In one embodiment, the polypeptide toxin comprises three intrachain disulfide bonds and/or is a component of a venom of an Australian funnel web spider... Agent: Cantor Colburn, LLP

20070066533 - Cell adhesion inhibitors: Cell adhesion inhibitors can interact with VLA-4 molecules and inhibits VLA-4 dependent cell adhesion. An inhibitor including a polyethylene glycol moiety can have advantageous pharmaceutical properties.... Agent: Steptoe & Johnson LLP

20070066532 - Compositions and methods for treatment of muscle pain and muscle wasting: Compositions and methods for alleviating the symptoms associated with muscle pain in general or muscle wasting are provided. The compositions are based on use of androgens, either alone or in combination with other hormones, including growth hormone.... Agent: Licata & Tyrrell P.C.

20070066525 - Compositions and therapeutic methods using morphogenic proteins: The present invention provides pharmaceutical compositions comprising at least two morphogenic proteins, particularly those belonging to the BMP protein family. This invention also provides implantable morphogenic devices comprising a first morphogenic protein and a second morphogenic protein combination disposed within a carrier, that are capable of inducing tissue formation. Methods... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070066527 - Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing alzheimer's disease-like pathology: The present invention relates to methods for treating, preventing, or diagnosing the pathology of progressive cognitive disorders resulting from accumulation of an amyloid peptide, in particular, Alzheimer's disease, Down's syndrome and cerebral amyloid angiopathy, in mammalian subjects using a composition comprising therapeutically effective amount of a leptin, leptin mimic, leptin... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070066524 - Mammalian iap gene family, primers, probes and detection methods: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primer and probes for the identification and isolation of additional IAP genes.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070066526 - Method for reducing risk of and extent of injury due to stroke in hypertensive subjects: A method for reducing the risk of stroke in a subject with hypertension is described. The method includes administering an inhibitor of delta protein kinase C (PKC) to the subject. Also described is a method for improving the survival from stroke in a subject with chronic hypertension by treating the... Agent: Perkins Coie LLP

20070066528 - Methods and compositions for treating polycystic ovary syndrome: The present invention relates to methods of treating polycystic ovary syndrome (PCOS) comprising administering glucagon-like peptide-1 (GLP-1), exendin, and analogs and agonists thereof, to subjects suffering therefrom.... Agent: Arnold & Porter LLP (18528) Attn IPDocketing Dept.

20070066530 - Methods for modulating gastric secretion using prokineticin receptor antagonists: The invention provides methods of modulating gastric acid secretion by administering an amount of a prokineticin receptor antagonist effective to alter one or more indicia of gastric acid secretion, wherein the antagonist contains an amino acid sequence at least 80% identical to amino acids to 7 to 77 of SEQ... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070066531 - Modified vitamin k-dependent polypeptides: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.... Agent: Fish & Richardson P.C.

20070066520 - Novel epidermal growth factor protein and gene, and methods of use therefor: Forms of epidermal growth factor that are resistant to proteolysis, and gene sequences encoding these forms and having codons optimized for usage by an industrial production organism, are provided.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066518 - Pharmaceutical composition for inducing apoptosis comprising a fusion protein between bfl-1 and green fluorescent protein or a gene encoding same: A pharmaceutical composition comprising a fusion protein between green fluorescent protein and Bfl-1 protein or a gene encoding the fusion protein, as well as a pharmaceutically acceptable carrier, is capable of efficiently inducing apoptosis and useful for treating cancer or cell hyperplasia.... Agent: Sughrue Mion, PLLC

20070066521 - Short rna-binding proteins: The present invention provides compositions, kits, and methods that may be used to bind short RNA molecules, including miRNA and/or siRNA molecules. Such compositions and methods are useful in research and experimental systems to investigate the effects of, for example, miRNAs and/or siRNAs on endogenous and/or exogenous gene expression. Isolated... Agent: Bryan Cave LLP

20070066522 - Tumor inhibition by modulating sprouty expression or activity: Methods are provided for identifying compounds that decrease the expression or activity of an overexpressed Sprouty protein in certain cancers. Such compounds can be useful for treating cancers in which a Sprouty protein is overexpressed. Also provided are therapeutic formulations and pharmaceutical formulations for treating cancers characterized by overexpression of... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070066519 - Use of human growth hormone in multiple system atrophy: The invention relates to the use of a substance, which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance, which stimulates release or potentiates the activity of endogenous hGH, for treatment and/or prevention of Parkinsonism-Plus Syndromes. In particular, the invention relates to the use... Agent: Howrey LLP

20070066535 - Novel haptotactic peptides: Novel cell attachment peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains are disclosed. The novel peptides, derived from proteins related to fibrinogen including a peptide adjacent to fibrinogen γ-chain C terminus denoted pre-Cγ possess cell attraction activities, and are useful in pharmaceutical compositions.... Agent: Cooper & Dunham, LLP

20070066534 - Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides... Agent: Fenwick & West LLP

20070066536 - Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators: Methods for treating hormone associated conditions, such as endometriosis, uterine leiomata, ovarian cancer, breast cancer, or vaginal bleeding, using LHRH antagonists and selective estrogen receptor modulators are disclosed. The methods include administering to a subject a combination of an LHRH antagonist and a selective estrogen receptor modulator. Pharmaceutical compositions and... Agent: Lahive & Cockfield, LLP

20070066537 - Compounds and compositions for prevention of overdose of oxycodone: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of... Agent: Hunton & Williams LLP Intellectual Property Department

20070066538 - Treatment of wounds: An isolated protein, for use in treatment of wounds, is characterized in that it is secreted by the organism Lucilia sericata and it exhibits proteolytic activity against FITC-casein at a pH of 8.0 to 8.5. The protein exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC, and its proteolytic activity... Agent: Edwards & Angell, LLP

20070066539 - Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof: The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P2-P1 with P1=(A) and P2=(B), for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic... Agent: Clark & Elbing LLP

20070066541 - Compositions and methods for the intraocular transport of therapeutic agents: Membrane transporter-targeted therapeutic agents and methods of making and using the same.... Agent: Stephen Donovan Allergan, Inc.

20070066540 - Growth hormone secretagogue receptor type 1a agonists: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.... Agent: Novo Nordisk, Inc. Patent Department

20070066542 - Novel imidazole derivatives, their preparation and their use as medicaments: m

20070066543 - Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity: The invention provides a method for treating an animal suffering from a disease associated with reduced activity of a lysosomal hexosaminidase by administering to the animal an effective amount of a compound which increases the activity of the hexosaminidase.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070066544 - 3-decladinosyl 9a-n-carbamoyl and 9a-n-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a: their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to intermediates for synthesis of other macrolide compounds with antibacterial activity, to the process for their preparation, to their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates, to the process for the preparation... Agent: Darby & Darby P.C.

20070066545 - Vaginal compositions for treating pelvic tissue infections and traumas: A pharmaceutical composition for use in the treatment and/or prevention of a pelvic tissue infection by vaginal administration comprises an antibiotic and a pharmaceutically acceptable carrier or diluent.... Agent: Ray L Weber Renner Kenner Greive Bobak Taylor & Weber

20070066546 - Compositions for the reversible thioesterification of signaling proteins and methods of using same: Avicins and other thioesterification agents are used to modify cysteine groups of signaling proteins in order to modify their activity. Pathologies associated with signaling proteins which are regulatable through this method are treated using these thioesterification agents. These pathologies include those involving proteins which modulate physiologic redox status of organisms... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066556 - Antisense antiviral compound and method for treating picornavirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Picornaviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of Enterovirus and/or Rhinovirus infection in a mammal. The antisense antiviral... Agent: Perkins Coie LLP

20070066551 - Aptamer medicinal chemistry: The invention relates generally to the field of nucleic acids and more particularly to aptamers useful as therapeutics, diagnostics and in research such as for target validation. The invention further relates to materials and methods for enhancing aptamers for use in therapeutics, diagnostics and research.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066550 - Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics: The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066555 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070066548 - Globin variant gene methods and compositions: Methods are provided for treating a mammal having a disease, where the disease is caused by a globin disease mutation or a mutation in globin regulation, and where the globin disease mutation or the mutation in globin regulation causes production of a deleterious globin chain or production of insufficient quantities... Agent: Amster, Rothstein & Ebenstein LLP

20070066553 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, PC

20070066554 - Immunostimulatory nucleic acids: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than... Agent: Wolf Greenfield & Sacks, PC

20070066547 - Ligands: Aptamers that bind to viral envelope proteins, in particular those that bind to the envelope glycoprotein gp120 of HIV are disclosed, The use of these aptamers for screening potential therapeutic targets and in the treatment of HIV infections is also described.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070066549 - Modulation of elf4e expression: Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with... Agent: Eli Lilly & Company

20070066557 - Modulation of glucocorticoid receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for treatment of diseases... Agent: Elmore Patent Law Group

20070066558 - Molecular determinants of myeloma bone disease and use thereof: To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble... Agent: Benjamin Aaron Adler Adler & Associates

20070066552 - Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids: Compositions and methods for preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid comprised in a solid or semi-solid formation or in a transdermal or transcutaneous delivery device are disclosed. Also disclosed are compositions of a nucleic acid capable of preventing or... Agent: Fulbright & Jaworski L.L.P.

20070066559 - Compounds for the treatment of pain: Use of compounds of the following formula as analgesics, in particular antihyperalgesics, is described: wherein R is C1-4 alkoxy, and X is H or OH.... Agent: Fish & Richardson PC

20070066560 - Partial and full agonists of a1 adenosine receptors: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.... Agent: Cv Therapeutics, Inc.

20070066561 - Drug delivery and targeting with vitamin b12 conjugates: Vitamin B12 can be conjugated to anti-cancer drugs to deliver these drugs selectively to tumors, wherein the conjugates bind to transcobalamin. The complex of vitamin B12 and transcobalamin is recognized and taken into cells by specific cell surface receptors which are overexpressed in rapidly dividing cells.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070066562 - Fungicidal active substance combinations: t

20070066563 - Method of preparation of a fungal glucane hydrogel having antibacterial and immunostimulant activity, and use thereof: A method of preparation of a fungal glucane hydrogel having antibacterial and immunostimulant activity by alkaline deproteination and subsequent elimination of water-soluble components consists in that the obtained insoluble glucan is subsequently hydrated by wet grinding at a rotational speed of 3000 to 9000 rpm for 10 to 20 min.... Agent: Oppedahl Patent Law Firm LLC

20070066564 - Sulfotransferase inhibitor: In the formula, each of R1, R2, and R3 independently represent(s) SO3− or H which may have a substituent, provided that at least one thereof represents SO3−; X represents OR4, SR4, N(R4)2, or C(R4)3, R4 independently represents H, alkyl, alkenyl, alkynyl, acyl, aryl, or aralkyl group; one of R5 and... Agent: Knobbe Martens Olson & Bear LLP

20070066565 - Cyclic maltosylmatose: An object of the present invention is to provide an option of non-reducing saccharide by providing a novel non-reducing saccharide composed of glucose as constituents and to provide a novel enzyme forming the non-reducing saccharide, a method and process for producing the same, a DNA encoding the enzyme, a recombinant... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070066566 - 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3:

20070066567 - Use of phospholipid arachidonic acids for increasing muscle mass in humans: This invention discloses a method of increasing muscle mass comprising administering phospholipid arachidonic acid to a human in need thereof.... Agent: Todd S. Parkhurst Holland & Knight LLP

20070066569 - Process for the preparation of bisphosphonic acid: i

20070066568 - Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators: This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070066570 - Methods for treating sleep disorders: A method of treating a subject for a sleeping disorder, comprising administering to a subject in need of treatment for a sleeping disorder an effective amount of an N-substituted azaheterocyclic compound as described herein.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070066572 - Neuroprotection by positively-charged nitroxides: Methods for treating neurodegenerative disorders characterized by abnormal reactive oxygen species including administering to a subject an effective amount of a mitochondria-targeted nitroxide. Likewise, methods for mitigating reactive-oxygen species-mediated apoptosis including administering an effective amount of a mitochondria-targeted nitroxide.... Agent: Quarles & Brady LLP

20070066571 - Novel bisphosphonates having anti-inflammatory and/or pain-killing properties: This invention describes new and novel bisphosphonate conjugates having anti-inflammatory and/or pain-killing properties.... Agent: Richard F. Stockel

20070066573 - Pyrrole and pyrazole derivatives as potentiators of glutamate receptors: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate... Agent: Eli Lilly & Company

20070066574 - Myo-inositol hexaphosphate for topical use: The invention relates to a composition that includes myo-inositol hexaphosphate applied by topical administration for utilisation in the treatment or prevention of a disease associated with the development of heterogeneous nucleants in a soft tissue. Said composition can be used for manufacturing a drug for the treatment of a disease... Agent: Wolf, Block, Shorr And Solis-cohen LLP

20070066575 - Methods and compositions for mitigating pain: Methods and therapeutic compounds for treating pain, mitigating inflammation, effecting analgesia and/or effecting sedation in a subject are described. A subject is administered an effective amount of a therapeutic compound which is a nitrate ester. Novel pharmaceutical compositions are also described.... Agent: Clark & Elbing LLP

20070066576 - Hif hydroxylase inhibitors: The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070066577 - Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same: A novel benzoxazole derivative of formula (I) or a pharmaceutically acceptable salt thereof is effective for inhibiting 5-lipoxygenase which is useful for preventing or treating leukotriene-related diseases. The prevention also provides a pharmaceutical composition containing same and a method for preventing or treating leukotriene-related diseases.... Agent: David A. Einhorn, Esq. Anderson Kill & Olick, P.C.

20070066578 - 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same: It is an object of the present invention to inhibit browning of a 5-aminosalicylic acid solid preparation, and to maintain for an extended period the properties of the 5-aminosalicylic acid solid preparation the same as they were at the time of the manufacturing the preparation. The present invention provides a... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070066579 - 5-androsten-3beta-ol steroid intermediates and processs for their preparation: The present invention provides 5-androsten-3β-ol steroid intermediates and processes for their preparation.... Agent: Warner-lambert Company

20070066580 - Novel aldosterone antagonists and uses thereof: The present invention relates to novel compounds that are aldosterone receptor antagonists, to pharmaceutical compositions containing the aldosterone receptor antagonists, and to methods of treatment using the same.... Agent: Darby & Darby P.C.

20070066581 - Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors: The invention provides a new class of deoxynojirimycin analogues, or pharmaceutically acceptable salts thereof which can suitably be used for the treatment of a disease selected from the group consisting of insulin resistance, Gauger disease, inflammatory diseases, hyperpigmentation and/or inflammatory skin conditions, overweight and obesity, lysosomal storage disorders, fungal diseases,... Agent: Sughrue Mion, PLLC

20070066582 - Diaminoalcohols as therapeutic compounds: e

20070066587 - Substituted azetidine compounds, their preparation and use as medicaments: The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070066584 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Fish & Richardson PC

20070066586 - Aniline derivatives: e

20070066585 - Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents: The present invention relates to novel heterocyclyl-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070066583 - Monocyclic and bicyclic compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1... Agent: Townsend And Townsend And Crew, LLP

20070066588 - Benzothiazole cyclobutyl amine derivatives: m

20070066589 - Method of preparing 10th-dibenzo[b,f][11,4]thiazepin-11-one: Disclosed is a method of preparing 10H-dibenzo[b,f][1,4]thiazepin-11-one, including reacting dithiosalicylic acid with 1-chloro-2-nitrobenzene in a basic aqueous solution in the presence or absence of a reducing agent, to prepare 2-(2-nitrophenylsulfuryl)benzoic acid; subjecting the 2-(2-nitrophenylsulfuryl)benzoic acid to nitro group reduction in the presence of hydrogen, a solvent and a heterogeneous metal... Agent: Abelman Frayne & Schwab

20070066591 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by inhibiting the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070066590 - Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism: The present invention relates to certain substituted aryl and heteroaryl derivatives as shown in Formula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.... Agent: Cozen O'connor, P.C.

20070066592 - Fused bicycloheterocycle substituted quinuclidine derivatives: wherein n is 0, 1, or 2; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds... Agent: Robert Deberardine Abbott Laboratories

20070066593 - Use of carbamazepine derivatives for the treatment of agitation in dementia patients: The present invention relates to the use of a compound of formula (I) wherein (a) R1 and R2 together form an oxy group or (b) R1 is hydrogen and R2 is hydroxy or acetoxy, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment... Agent: Novartis Corporate Intellectual Property

20070066594 - Crystalline forms fenoldopam mesylate: The invention provides new crystalline forms of fenoldopam mesylate, i.e. fenoldopam mesylate Type I, fenoldopam mesylate Type III, fenoldopam mesylate Type V, and fenoldopam mesylate Type VI, methods of preparing the crystalline forms, and pharmaceutical compositions comprising the fenoldopam mesylate crystalline forms of the invention.... Agent: Kenyon & Kenyon LLP

20070066595 - Selective estrogen receptor modulators: The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.... Agent: Eli Lilly & Company

20070066596 - Pesticidal 5-substituted-oxalkylamino-1-arylpyrazole derivatives: The imvention relates to 5-sub-stituted-oxyalkylaminopyrazole derivatives of formula (I) or salts thereof wherein the various symbols are as defined in the description, to processes for their preparation, to compositions thereof, and to their use for the control of pests (including arthropods and helminths).... Agent: Buchanan, Ingersoll & Rooney PC

20070066597 - Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders: The invention relates to methods of using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat lower urinary tract and related disorders.... Agent: Alston & Bird LLP

20070066598 - Compounds: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.... Agent: Fish & Richardson PC

20070066600 - Compounds: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.... Agent: Fish & Richardson PC

20070066599 - New compounds: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.... Agent: Fish & Richardson PC

20070066601 - Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist: The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a H3 receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized... Agent: Darby & Darby P.C.

20070066602 - Process for making olanzapine form i: Olanzapine Form I can be made by converting olanzapine benzoate to olanzapine base in an aqueous environment and isolating and drying the resulting solid olanzapine.... Agent: SynthonIPInc

20070066603 - Method for alleviating climacteric symtoms: The present invention is a method for alleviating at least one climacteric symptom in a climacteric subject using an anticholinergic agent. To illustrate the instant invention, homatropine was shown to relieve hot flushes in peri-menopausal and post-menopausal women.... Agent: Cislo & Thomas, LLP

20070066604 - Diaminoalcohols as therapeutic compounds: e

20070066606 - Benzylbenzimidazolyl derivatives: Novel benzyl-benzimidazolyl derivatives as inhibitors of tyrosine kinases, particularly TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR, for the treatment of tumors, according to formula (I), wherein the radicals R1, R2, r and s are defined according to Claim (1).... Agent: Millen, White, Zelano & Branigan, P.C.

20070066605 - Fungicides: Fungicidal compositions having the general formula (1): formula (1) wherein W and Y are both N and X and Z are both CR8 or X and Z are both N and W and Y are both C6, R8 is H, halo, C1-4 alkyl, C1-4alkoxy or halo(C1-4)alkyl; R and R2 are... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070066609 - Long acting beta-2-agonists and their use as medicaments: R2, R2′, R2″, and R′″ are each independently hydrogen, C1-6-alkyl, halogen-C1-6-alkylene, OH, HO—C1-6-alkylene, —O—C1-6-alkyl, C6-10-aryl, C6-10-aryl-C1-4-alkylene, C6-10-aryl-C1-6-alkylene-O, COOH, COOC1-6-alkyl, O—C1-6-alkylene-COOH, O—C1-6-alkylene-COOC1-6-alkyl, NHSO2—C1-6-alkyl, CN, NH2, NH—C1-6-alkyl, N(C1-6-alkyl)2, NO2, S—C1-6-alkyl, SO2—C1-6-alkyl, SO—C1-6-alkyl, O(CO)C1-6-alkyl, COC1-6-alkyl, NHCOC1-6-alkyl, or halogen; and n is 0, 1, or 2, or an optical isomer thereof, or a corresponding... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070066608 - Novel indole derivatives with an improved antipsychotic activity: The present invention relates to a novel indol derivative according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables R1, R2, R3, R4, R5, p, a1═a2a3═a4, Z1—Z2, X and... Agent: Philip S. Johnson Johnson & Johnson

20070066607 - Quinoline-2-one derivatives for the treatment of airways diseases: free or salt form, wherein —C—Y—, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.... Agent: Novartis Corporate Intellectual Property

20070066610 - Acylhydrazones as kinase modulators: where R1, R2 and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell... Agent: Philip S. Johnson Johnson & Johnson

20070066611 - Method for the production of 4-(4-aminophenyl)-3-morpholinone: The present invention relates to a process for preparing 4-(4-aminophenyl)-3-morpholinone by reacting 4-(4-nitrophenyl)-3-morpholinone with hydrogen in the presence of a hydrogenation catalyst, characterized in that the reaction is effected in an aliphatic alcohol.... Agent: Jeffrey M. Greenman

20070066614 - Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1: e

20070066613 - Imidazole compounds for the treatment of neurological disorders: wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds... Agent: Pfizer Inc

20070066612 - Substituted pyrimidine derivatives: e

20070066615 - Heterocyclic compounds: The present invention relates to the area of blood clotting. The invention relates in particular to certain heterocyclic compounds, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases.... Agent: Jeffrey M. Greenman

20070066616 - Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor: Provided herein are compounds and methods of using compounds that selectively inhibit binding to one or more docking domain regions of an extracellular signal-regulated kinase (ERK) to inhibit in a cell having an extracellular signal-regulated kinase activity. Such methods may be used to inhibit cell proliferation of a neoplastic cell,... Agent: Benjamin Aaron Adler Adler & Associates

20070066617 - Isoxazoline-substituted benzamide compound and pesticide: wherein A1, A2 and A3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C1-C6haloalkyl, etc., Y is halogen atm, C1-C6alkyl, etc., R1 is C1-C12alkyl arbitrarily substituted with R16, C3-C2alkenyl, arbitrarily substituted with R16 is oxygen atom or sulfur atom,... Agent: Oliff & Berridge, PLC

20070066618 - Use of ep4 receptor ligands in the treatment of il-6 involved diseases: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.... Agent: Warner-lambert Company

20070066619 - Compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity: The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.... Agent: Seed Intellectual Property Law Group PLLC

20070066620 - 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists: R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070066621 - Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin d: In its many embodiments, the present invention provides a novel class of 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridine, pyrazolo[1,5-c]pyrimidine, and 2H-Indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridine and imidazo[1,5-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070066622 - 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses: The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.... Agent: Jeffrey M. Greenman

20070066623 - Entry inhibitors of the hiv virus: The present invention relates to small molecules as entry inhibitors of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with other anti-retroviral agents. It further relates... Agent: Philip S. Johnson Johnson & Johnson

20070066624 - Chemokine receptor binding compounds: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus... Agent: Morrison & Foerster LLP

20070066625 - Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity: Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.... Agent: Moore & Van Allen PLLC

20070066626 - Compounds, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070066627 - Hydrazone derivatives for combatting harmful insects and arachnids: The present invention relates to a method for combating insects or arachnids which comprises contacting the insects or the arachnids, their habitat, breeding ground, food supply, plant, seed, soil, area, material or environment in which the insects or the arachnids are growing or may grow, or the materials, plants, seeds,... Agent: Hutchison Law Group PLLC

20070066628 - 5-aryl-indan-1-ol and analogs useful as progesterone receptor modulators: e

20070066629 - Fungicidal mixtures for controlling rice pathogens:

20070066630 - Nitrogen-containing heterocyclic compounds and methods of use thereof:

20070066631 - Pyrazolyl substituted xanthines: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent: Proskauer Rose LLP

20070066632 - Fused bicyclic inhibitors of tgfbeta: Certain appropriately substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with excessive TGFβ activity and certain viral disorders.... Agent: Morrison & Foerster LLP

20070066633 - Quinazoline compounds: wherein ring A is phenyl or a 5- or 6-membered heterocyclic ring as defined herein; Z is —O—, —NH— or —S—; m is an integer from 0 to 5 inclusive; R1 is hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be... Agent: Morgan Lewis & Bockius LLP

20070066635 - Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor: Compositions comprising Compound I, wherein the Compound I is present in one or more polymorphic forms. Also provided are kits and articles of manufacture with compositions comprising one or more polymorphs of Compound I, and methods of using the compositions to treat various diseases.... Agent: Takeda San Diego, Inc.

20070066636 - Polymorphs of tartrate salt of 2-[2-(3-(r)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6h-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor: Compositions comprising Compound I, wherein the Compound I is present in one or more polymorphic forms. Also provided are kits and articles of manufacture with compositions comprising one or more polymorphs of Compound I, and methods of using the compositions to treat various diseases.... Agent: Takeda San Diego, Inc.

20070066634 - Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites: m

20070066637 - 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators:

20070066638 - Ryanodine receptor blockers for treating pain: The present invention provides a method of preventing or ameliorating pain in a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action causing said pain, an effective amount of a ryanodine antagonist, such as dantrolene, to inhibit or prevent pain.... Agent: Allergan, Inc.

20070066639 - Oxime substituted imidazoquinolines: Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: 3m Innovative Properties Company

20070066641 - Compounds and methods for development of ret modulators: Compounds active on Ret and/or FGFR are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and... Agent: Foley & Lardner LLP

20070066640 - Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070066644 - 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3h-imidazo[4,5-b]pyridin-3-yl]piperidine: and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070066643 - Methods of treating middle-of-the-night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: Townsend And Townsend And Crew, LLP

20070066645 - Novel compounds: e

20070066642 - Novel imidazopyridine compound ii with therapeutic effect: The present invention relates to imidazo pyridine derivatives of the Formula I which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastric acid related diseases or gastrointestinal inflammatory diseases.... Agent: White & Case LLP Patent Department

20070066646 - Compounds for inhibiting copper-containing amine oxidases and uses thereof: This invention is directed to inhibitors of copper-containing amine oxidases (E.C. 1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-1), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070066647 - Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders: i

20070066648 - Method of treating or inhibiting the development of brain inflammation and sepsis: A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070066649 - Method of treating or inhibiting the development of brain inflammation and sepsis: A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070066650 - 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR. Also provided are methods of making such compounds and pharmaceutical compositions.... Agent: Fish & Richardson, PC

20070066651 - Pyrazoline derivatives useful for the treatment of cancer: Compounds of formula (I) wherein: X is selected from the group consisting of trihalomethyl, C1-C6 alkyl, and a group of formula (II) wherein: R3 and R4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C1-C6 alkyl; C1-C6 alkoxy; carboxy; C1-C6 trihaloalkyl; and cyano; Z is selected... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070066652 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of general formula: Formula (I) wherein R1, R2, R3 and A are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Cozen O'connor, P.C.

20070066653 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of general formula: Formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Cozen O'connor, P.C.

20070066654 - Inhibitory or blocking agents of molecular generating and/or inducing functions: m

20070066657 - Biphenyl-pyrazolecarboxamide compounds: The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking... Agent: Edwards & Angell, LLP

20070066655 - Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists: Compounds of general formula: (Formula (I)) wherein R1, R2, R3, R4 and R5 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain and anxiety.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070066656 - Novel stable polymorphic forms of an anticonvulsant: Stable polymorphic forms III, IV and substantially amorphous form of an anticonvulsant, tiagabine hydrochloride.... Agent: Merchant & Gould PC

20070066658 - Opioid receptor antagonists: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3′, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases... Agent: Eli Lilly & Company

20070066660 - Benzimidazolyl derivatives: The invention relates to the novel compounds of formula (I) wherein R1, R1, L, E, G, M, Q, U, R2, m, p and q are defined as in claim 1. The novel compounds are tyrosinkinase inhibitors, especially TIE-2 inhibitors, and Raf kinase inhibitors and can be used in the treatment... Agent: Heller Ehrman LLP

20070066659 - Use of tenatoprazole for the treatment of gastroesophageal reflux disease: The invention relates to a novel therapeutic application of tenatoprazole. Tenatoprazole and the salts thereof can be used in the production of a medicament for the treatment of atypical and esophageal symptoms of gastroesophageal reflux, gastrorrhagia and dyspepsia.... Agent: Buchanan, Ingersoll & Rooney PC

20070066661 - Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus: Insulin sensitivity increasing substances (ISIS), including but not limited to D-chiro-inositol, thiazolidinedione and derivatives, and biguanides, are useful in the treatment of hair loss and other disorders of the pilosebaceous apparatus (hirsutism, acne, etc.) associated with conditions of excess insulin and/or insulin resistance. The treatment comprises administering to a mammal,... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070066662 - Process for the preparation of thiazolidinedione derivatives: wherein A1, R1, A2 and n are as defined in relation to formula (I), characterised in that the reduction reaction is carried out using a hydrogen pressure above 20 psi; and thereafter if required forming a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I).... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070066663 - 3-aminopiperidines and 3-aminoquinuclidines as inhibitors of monoamine uptake: e

20070066664 - Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses, materials for their synthesis: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing... Agent: Pfizer Inc

20070066665 - Compounds and methods for the diagnosis and treatment of amyloid associated diseases: The invention is in general directed to compounds and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, methods of screening for compounds useful in preventing or alleviating the symptoms of amyloid-associated diseases, methods of diagnostic imaging of... Agent: Biotechnology Law Group C/o Portfolioip

20070066666 - Thiazole compounds: e

20070066667 - Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions:

20070066668 - Isoxazolo derivatives:

20070066669 - Fungicidal active combinations spiroxamine, prothioconazole and tebuconazole: The present invention relates to a novel active compound combination that is highly suitable for controlling phytopathogenic fungi which contains the known 8-tert-butyl-1,4-dioxaspiro[4.5]decan-2-ylmethyl(ethyl)(propyl)amine (spiroxamine) and other known active compounds.... Agent: Bayer Cropscience Lp Patent Department

20070066670 - Substituted benzimidazoles and their use for inducing apoptosis: wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis... Agent: Gibbons, Del Deo, Dolan, Griffinger & Vecchione

20070066671 - Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas: e

20070066672 - Benzimidazole derivatives and use thereof as peptide deformylase inhibitors: Benzimidazole compounds of the general formula (I) and pharmaceutically acceptable salts or esters thereof are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections, for example infections fully or partly... Agent: Edwards & Angell, LLP

20070066673 - Iodopyrazolyl carboxanilides: in which R1, R2, R3, R4, R5, R6 and Z are as defined in the disclosure, to a plurality of processes for preparing these compounds and to their use for controlling unwanted microorganisms. This invention further relates to novel intermediates and their preparation.... Agent: Bayer Cropscience Lp Patent Department

20070066674 - Tricyclic imidzopyridines for use as gastric secretion inhibitors:

20070066675 - 5-aryl-indan-1-one and analogs useful as progesterone receptor modulators:

20070066676 - Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bh-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives: wherein R is H, alkyl, acyl, aryl, aroyl or —C(O)R′; R′ is alkyl or aryl; R1, R2, R4 and R5 are H, —OH, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl or alkoxy, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylamino, acyl, aryl or aroyl; R3 is H, alkyl, cycloalkyl, alkoxy, fluorinated... Agent: Wyeth Patent Law Group

20070066677 - (2s,4s)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-i-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof: The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-β-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070066678 - Crystalline sodium atorvastatin: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070066679 - Crystalline sodium atorvastatin: Crystalline sodium atorvastatin, compositions containing the same and methods for the production thereof.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070066680 - Benzofurans and benzothiophenes: y

20070066681 - Pharmaceutical composition for treating fatty liver or hepatic disease:

20070066682 - Arylalkylamine vanadium (v) salts for the treatment and/or prevention of diabetes mellitus:

20070066683 - Selective peroxisome proliferator activated receptor modulators: The present invention is directed to a novel compound, its composition and use of a compound having a structural formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomers thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome... Agent: Eli Lilly & Company

20070066684 - Compounds and preparations having antiviral effect: wherein is R1 —(CH2)aX(CH2)bCH3, —(CH2)cX(CH2)dYCH3, —CO(CH2)eCH3 or —(CH2)fCH3 R2 is —CO(CH2)nCH3, R3, R4 and R5 are hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, X and Y are O or S, and each of a-f and n is a number, and having a specific safety index S.I.=CC50/EC50 of... Agent: Oliff & Berridge, PLC

20070066685 - Process for producing 1, 4-dihydoxy-2-naphthoic acid: A process for producing 1,4-dihydroxy-2-naphthoic acid, comprising initiating the culture of 1,4-dihydroxy-2-naphthoic acid producing bacteria belonging to propionic acid bacteria under anaerobic conditions and culturing the bacteria under aeration into a medium when the concentration of a carbon source in the medium is 3.5% by mass or less.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070066686 - Infusion preparation containing (2r)-2-propyloctanoic acid as at the active ingredient: The present invention relates to an infusion preparation which is useful for neurodegenerative diseases, which comprises (2R)-2-propyloctanoic acid or a salt thereof and a basic metal ion which is supplied from a metal salt or a metal hydroxide of weak acid, preferably about 1 to about 5 equivalents of a... Agent: Sughrue-265550

20070066687 - Amide-based compound, polyolefin resin composition and molded product: wherein a represents an integer of 2 to 6, R1 represents a C2-30 saturated or unsaturated aliphatic polycarboxylic acid residue, and the aliphatic polycarboxylic acid has a valency of 2 to 6, and two to six R2 groups are the same or different, and each represent a trans-2-alkylcyclohexylamine residue or... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070066688 - Cyclopentyl derivatives: This invention is related to novel cyclopentyl derivatives of the following general Formula (I), wherein X is methylene, oxygen, sulphur or a NR7 group; R1 is a straight or branched C1-C8 alkyl or C3-C8 alkenylene or C3-C8 alkynylene chain, optionally substituted with CF3, phenyl, phenoxy or naphthyl, the aromatic rings... Agent: Young & Thompson

20070066689 - Association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it: Association comprising agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in association with a thymoregulatory agent. Medicinal products containing the same which are useful in the treatment of mood disorders.... Agent: The Firm Of Hueschen And Sage

20070060498 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070060499 - Chloroquine combination drugs and methods for their synthesis: This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled... Agent: Kenneth M. Kosak

20070060501 - Methods and therapies for potentiating a therapeutic action of an opioid receptor agonist and inhibiting and/or reversing tolerance to opioid receptor agonists: Combination therapies of an opioid receptor agonist and an alpha-2 receptor antagonist in an amount effective to potentiate, but not antagonize, a therapeutic effect of the opioid receptor agonist are provided. Also provided are methods for use of these combination therapies in potentiating the therapeutic effects of opioid receptor agonists,... Agent: Licata & Tyrrell P.C.

20070060500 - Pharmaceutical compositions for prevention of overdose or abuse: The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that... Agent: Hunton & Williams LLP Intellectual Property Department

20070060497 - Reagents for modifying biopharmaceuticals, the use and production thereof: The present invention relates to compounds which are suitable for coupling to pharmaceuticals, in particular biopharmaceuticals, and to conjugates composed of the compounds and biomolecules or pharmaceutical active compounds. The compounds according to the invention can be readily formed by means of multicomponent reactions. The invention also relates to the... Agent: Fitch Even Tabin And Flannery

20070060502 - Substituted propane phosphinic acid derivatives: e

20070060503 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070060504 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070060505 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070060506 - Compositions and methods for treating bacteria: The present invention relates to the field of bacteriology. In particular, the present invention provides compositions (e.g., comprising a lantibiotic and mupirocin or gentamicin) and methods of treating (e.g., killing or inhibiting growth of) bacteria. For example, the present invention provides pharmaceutical compounds (e.g., comprising a lantibiotic and mupirocin or... Agent: Medlen & Carroll, LLP

20070060507 - Growth factor homolog zvegf3: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the... Agent: Zymogenetics, Inc. Intellectual Property Department

20070060508 - Binding molecules: The invention pertains to binding molecules consisting of a carrier structure of at least one cyclic molecular subunit and at least two side chain subunits, wherein the side chain subunits are polypeptide chains consisting of natural and/or unnatural D- and/or L-amino acids and the side chain subunits are covalently bonded... Agent: Jacobson Holman PLLC

20070060509 - Endoparasiticidal compositions for topical application: The present invention relates to transdermally applicable compositions comprising cyclic depsipeptides and/or praziquantel, and to their preparation and their use for controlling endoparasites.... Agent: Richard S. Bullitt Bayer Healthcare LLC

20070060510 - Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Edwards & Angell, LLP

20070060511 - Combinations of immunosupressive agents for the treatment or prevention of graft rejections: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute... Agent: Novartis Corporate Intellectual Property

20070060514 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070060512 - Dipeptidyl-peptidase protected protein: The present invention provides modified therapeutic polypeptides or peptides partially or completely protected from DPP activity. The modified polypeptides or peptides comprise at least one additional amino acid at the amino terminus. The modified therapeutic polypeptides or peptides are useful in the treatment of diseases such as diabetes.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070060515 - Epithelial cell specific growth factor keratinocyte growth factor (kgf): Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These... Agent: Heller Ehrman LLP

20070060516 - Her-2 peptides: Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.... Agent: Calfee Halter & Griswold, LLP

20070060519 - Hsp therapy in conjunction with a low antigenicity diet: The present invention fragments and analogs of heat shock proteins in combination with a low antigenicity diet for suppression, prevention and treatment of diabetes. The invention is exemplified using DiaPep277™, an analog of residues 437-460 of human Hsp60 in combination with a hydrolyzed casein diet. The invention further relates to... Agent: Winston & Strawn LLP Patent Department

20070060521 - Inhibition of stat3 signal transduction for human cancer therapy: Signal Transducer and Activator of Transcription (STAT) proteins have a fundamental role cell signaling, and are activated by a large number of cytokines and growth factors. One member of the STAT family, STAT3, has a critical role in oncogenesis. The present invention relates generally to disruption of the pathway of... Agent: Fish & Richardson P.C.

20070060518 - Melanoma antigen peptide analogues: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which... Agent: Knobbe Martens Olson & Bear LLP

20070060513 - Method for increasing the serum half-life of a biologically active molecule: A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased serum half-life, e.g., human urokinase plasminogen activator (human “uPA” or “hUPA”) or... Agent: Novartis Vaccines And Diagnostics Inc.

20070060517 - Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject. Methods of the present invention... Agent: Licata & Tyrrell P.C.

20070060520 - Use of anti-prolactin agents to treat proliferative conditions: The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.... Agent: Foley And Lardner LLP Suite 500

20070060522 - Soluble fibrin inhibitory peptides and uses thereof: The present invention demonstrated that soluble fibrin binds to both Mac-1 and ICAM-1-expressing cells and inhibited adherence of these cells and immune cytotoxicity, thus inducing immune suppression in cancer. Additionally, the present invention also demonstrated that soluble fibrin enhanced metastasis in an in vivo model. Furthermore, the present invention demonstrated... Agent: Benjamin Aaron Adler Adler & Associates

20070060524 - Prame peptide analogues: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which... Agent: Knobbe Martens Olson & Bear LLP

20070060523 - Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate: A process for the total synthesis of Distamycin, and synthetic poly-(4aminopyrrole-2-carboxamide) congeners thereof, using 1-methyl-4-forinylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate, is provided. The process finds application for both in solution and solid support synthetic technologies.... Agent: Modiano & Associati

20070060526 - Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070060527 - Orally administered small peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20070060525 - Thio-containing inhibitors of aminopeptidase p, compositions thereof and method of use: The present invention is directed to an α thio-containing compound that is capable of inhibiting the enzyme, membrane aminopeptidase P (mAPP or APP), whose natural substrate is bradykinin. The compound is useful as a pharmaceutical agent because by inhibiting bradykinin degradation, the compound allows bradykinin to exert its beneficial effects... Agent: Mcandrews Held & Malloy, Ltd

20070060528 - Administration of dipeptidyl peptidase inhibitors: Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.... Agent: Takeda San Diego, Inc.

20070060529 - Administration of dipeptidyl peptidase inhibitors: Pharmaceutical compositions comprising 2-[[2-[(3R)-3-Amino-piperidinyl)-5-fluoro-6-oxo-6H-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.... Agent: Takeda San Diego, Inc.

20070060530 - Administration of dipeptidyl peptidase inhibitors: Pharmaceutical compositions comprising 2-[6-(3-Amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of manufacture comprising the pharmaceutical compositions as well as methods of using the pharmaceutical compositions.... Agent: Takeda San Diego, Inc.

20070060531 - Pyrazole derivative, drug composition containing the same and production intermediate therefor: , and the other represents -Z-Ar wherein Z represents —O—, —S—, etc.; Ar represents an optionally substituted C6-10 aryl, etc.; R represents an optionally substituted C3-8 cycloalkyl, an optionally substituted C6-10 aryl, etc., pharmaceutically acceptable salts thereof, and prodrugs thereof, which exhibit an excellent inhibitory activity in human sodium/glucose cotransporter... Agent: Sughrue Mion, PLLC

20070060532 - Use of metformin and orlistat for the treatment or prevention of obesity: The present invention relates to anti-obesity pharmaceutical compositions comprising orlistat and metformin and to the use of combinations of metformin and orlistat to treat patients suffering from obesity.... Agent: Crowell & Moring LLP Intellectual Property Group

20070060533 - Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor: Provided are: an inhibitor of the formation of an advanced glycation end product (AGE) and aldose reductase for treating and preventing both various diseases relating to AGE formation, such as complications related to diabetes and various diseases relating to aldose reductase inhibition; pharmaceutical preparations, compositions, and food and drink that... Agent: Posz Law Group, PLC

20070060534 - Anthracycline analogs: Anthracycline analogs and their bioconjugates are useful as anticancer agents.... Agent: Townsend And Townsend And Crew, LLP

20070060535 - Targeted delivery of antiviral compounds through hemoglobin bioconjugates: This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to a protein, such as hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of... Agent: Mccarthy Tetrault LLP

20070060538 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070060537 - Methods and compositions for inhibiting viral infections: The application relates to inhibitors of POSH-associated E2 enzymes, such as the UBC13/UEV1 complex. Methods of using such RNAi inhibitors for treating viral disorders, such as, for example, HIV infection, are also described.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070060540 - Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences: The invention provides new methods of preventing and/or treating herpes virus infections, particularly reducing infection, one or more symptoms and recurrence of one or more symptoms of herpes simplex virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being... Agent: Morrison & Foerster LLP

20070060536 - Novel reagent compounds and methods of making and using the same: The present invention describes novel compounds and methods for capping reactive groups on support and during multistep synthesis. These new capping reagents are also useful for high quality synthesis on solid supports and surfaces used as microarrays, biosensors, or in general as biochips. The compounds are also useful for controlling... Agent: Tim Headley

20070060539 - Shc proteins as therapeutic targets in proliferative diseases: This invention provides methods for treating a subject afflicted with a proliferative disorder comprising administering to the subject a therapeutically effective amount of an agent which inhibits the expression of p46 Shc and/or p52 Shc, inhibits the activity of p46 Shc and/or p52 Shc in the subject, or increases the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070060541 - 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C... Agent: King & Spalding LLP

20070060542 - Method for preventing vascular disease: A method for orally administering vitamin preparations is described which combine vitamin B12 (B12, cobalamin) and folic acid (folate), with and without pyridoxine (B6), for preventing and treating elevated serum homocysteine (HC), cystathionine (CT), methylmalonic acid (MMA), or 2-methylcitric acid (2-MCA) levels. These metabolites have been shown to be indicative... Agent: Peter F Weinberg Gibson Dunn And Crutcher LLP

20070060543 - Aminated complex-type sugar chain derivatives and process for the production thereof: wherein R1 is H—(CO)—CH2X, —NH—(CO)—(CH2)b—CH2X, isothiocyanate group, —NH—(CO)a—(CH2)b—CO2H or —NH—(CO)a—(CH2)b—CHO, X being a halogen atom, a being 0 or 1, b being an integer of 1 to 4, R2 and R3 are a hydrogen atom or a group of the formulae (2) to (5) and may be the same or... Agent: Kubovcik & Kubovcik

20070060544 - 4-nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use: 4-nitro-2-[4′-methoxy)-phenoxy]-methane-sulfonanilide or the pharmaceutical acceptable salts or solvates or hydrates thereof are provided. Also provided is their mixture with povidone, phospholipids or cyclodextrin, as well as their pharmaceutical uses, particularly the use as a non-steroidal anti-inflammatory, analgetic agent.... Agent: Berenato, White & Stavish, LLC

20070060545 - Novel compounds: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene... Agent: Birch Stewart Kolasch & Birch

20070060546 - Novel use of mifepristone and derivatives therefor as hedgehog protein signaling pathway modulators and applications of same: The invention relates to a novel use of compounds having formula (I), including mifepristone (RU 486 or RU 38 486) and the derivative salts thereof, for the preparation of a medicament that can modulate(activate or inhibit) the Hedgehog protein signalling pathway, which is intended for the treatment of pathologies involving... Agent: Lowe Hauptman Berner, LLP

20070060547 - Heterocyclic boronic acid compounds: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7;... Agent: Foley & Lardner LLP

20070060548 - Modulation of epac, phospholipase cepsilon, and phospholipase d to treat pain: The present invention provides methods, compositions, and kits useful for reducing pain in a subject by inhibiting Epac, PLCε, and/or PLD. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that reduce pain. Methods of the invention can involve assaying test agent binding... Agent: Quine Intellectual Property Law Group, P.C.

20070060549 - Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders: The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension.... Agent: Merchant & Gould PC

20070060550 - Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders: Compounds of use for treating bipolar disorder may be identified by tests based on their effect on various reactions involved in PIns signalling in neuronal cells. Tianeptine may be used for treatment of bipolar disorder.... Agent: Ladas & Parry

20070060551 - Methods of using isothiazole derivatives to treat cancer or inflammation: Methods of using substituted 3,5-dithio-, disulfinyl-or disulfonyl-isothiazole derivatives to treat cancer or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20070060552 - Methods and compositions employing 4-aminophenylacetic acid compounds: The invention provides compositions comprising 4-APAA compounds and methods for treating disorders involving inflammation of the digestive system and/or mucosal tissues, such as inflammatory bowel disease. The methods and compositions of the invention also include combinations of 4-APAA compounds and 5-ASA compounds for treatment of such disorders.... Agent: Moore & Van Allen PLLC

20070060553 - 3-nitrogen-6,7-dioxygen steroids and uses related thereto: and pharmaceutically acceptable salts, solvates, stereoisomers and prodrugs thereof, in isolation or in mixture, wherein, independently at each occurrence: R1 and R2 are selected from hydrogen, oxygen so as to form nitro or oxime, amino, sulfate, and sulfonic acid, and organic groups having 1-30 carbons and optionally containing 1-6 heteroatoms... Agent: Seed Intellectual Property Law Group PLLC

20070060554 - Fungal and bacterial infection medication: A fungal and bacterial infection medication and method comprised of Ketoconazole (Ke), Enrofloxacin (Flo) and Diprionate (Dip). Diprionate for the purpose of treating fungal infections and decrease inflammation in animal ear canals.... Agent: Us Corporations, Inc.

20070060555 - Fatty acid modified forms of glucocorticoids: f

20070060556 - Barium salt of benzimidazole derivative: A barium salt of the S-enantiomer of omeprazole which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole is provided. Further, processes for preparing the barium salt, pharmaceutical compositions comprising the salt and a method of treatment or prevention of gastrointestinal ulcers comprising administration of the salt are provided.... Agent: Ranbaxy Inc.

20070060557 - Superoxide dismutase mimics for the treatment of optic nerve and retinal damage: Methods for preventing and treating damage to the optic nerve and/or retina by the use of SOD mimics, particularly pentaazacycle Mn(II) complex SOD mimics, are disclosed.... Agent: Alcon Research

20070060558 - Hybrid molecules qa where q is an aminoquinoline and a is an antibiotic residue, the synthesis and uses thereof as antibacterial agents: The invention concerns an aminoquinoline-antibiotic hybrid compound of general formula (I): Q—(Y1)p—(U)p—(Y2)p-A: wherein Q represents an aminoquinoline, (Y1)p(U)p—(Y2)p″ is an optional spacer and A is an antibiotic residue. The invention enables the antibiotic residue activity to be unexpectedly enhanced.... Agent: Le-nhung Mcleland

20070060559 - Penam crystals and process for producing the same: The present invention provides novel 2α-methyl-2β-[(1,2,3-triazol-1-yl)methyl]penam-3α-carboxylic acid benzhydryl ester (TMPB)-acetone crystals for use in the production of 2α-methyl-2β-[(1,2,3-triazol-1-yl)methyl]penam-3α-carboxylic acid 1,1-dioxide benzhydryl ester (TAZB); a process for producing the TMPB-acetone crystals comprising the steps of (A) concentrating a TMPB-containing organic solvent solution, (B) dissolving the resulting concentrate in acetone, and (C)... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070060560 - Process for producing the dihydrochloride of amino acids: An amino acid sulphate is transformed and isolated as the dihydrochloride, by neutralizing the sulphuric acid with sodium hydroxide, filtering off the precipitated sodium sulphate and reacidifying with hydrochloric acid.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070060561 - Proteasome inhibiting beta-lactam compounds:

20070060562 - Novel crystal form of pyrrolidylthiocarbapenem derivative: A novel crystal of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3 [[(3S,5S)-5-(sulfamoylaminomethyl)pyrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction preferably having main peaks at diffraction angles (2θ)=13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070060563 - Quinuclidine derivatives binding to mucarinic m3 receptors: n

20070060564 - Method of making antitussive medicine and relieving cough: Method for relieving cough using an effective antitussive chemical compound belonging to stemoamide or tuberostemospironine and method for manufacturing pharmaceutical compositions for treating or relieving cough in human and animal subjects which including a stemoamide or tuberostemospironine compound. In addition, the antitussive property of the compounds provides a method for... Agent: Knobbe Martens Olson & Bear LLP

20070060565 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070060568 - 5ht2c receptor modulators: e

20070060566 - Benzazepine derivatives as histamine h3 antagonists: The present invention relates to novel benzazepine derivatives of structure (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. These compounds act as histamine H3 antagonists.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070060567 - Novel indolyl derivatives which are l-cpt1 inhibitors: e

20070060569 - Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors: Compound of the formula wherein R represents OH or NHOH; R1 represents hydrogen, optically substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid or from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyrylsulfonyl; R3 represents hydrogen, optionally... Agent: Novartis Corporate Intellectual Property

20070060570 - Sulfopyrroles: The invention relates to compounds of formula (I) wherein R1 represents aryl, aralkyl or heteroaryl, R2 is aryl or heteroaryl and R3 is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20070060571 - Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use: The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived... Agent: Wilmerhale/nitromed

20070060573 - Acyltryptophanols: in which Q, X, Y, W, R1, R2, R3, R4, R5, R8 have the meanings stated in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of... Agent: Millen, White, Zelano & Branigan, P.C.

20070060572 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070060574 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: e

20070060575 - Aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070060577 - 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase: s

20070060578 - 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase:

20070060576 - Process for preparing benzimidazole thiophenes: The present invention provides a process for preparing benzimidazole thiophene compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070060579 - Synergistic fungicidal active substance combinations: e

20070060580 - Salicylate and gentisate salts of a piperazine compound: The present invention provides salt forms, and compositions thereof, useful as modulators of one or more GPCRs and which exhibit desirable characteristics for the same.... Agent: Choate, Hall & Stewart LLP

20070060582 - 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases: e

20070060581 - 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands: The present invention refers to new sulfonamide derivatives, of general formula (Ia, Ib, Ic), (I), (Ia, Ib, Ic), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070060583 - Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof: Compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4 and Z are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070060584 - Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers: Biaryl substituted thiazole, oxazole and imidazole compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treatment or prevention of... Agent: Merck And Co., Inc

20070060585 - Morpholine derivatives as norepinephrine reuptake inhibitors: a

20070060586 - Nitrooxyderivatives of antihypertensive drugs: The present invention relates to β-adrenergic blockers nitrooxyderivatives of general formula (I): A-(Y—ONO2)s and enantiomers and diastereoisomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and their use for the treatment of hypertension, cardiovascular diseases, glaucoma, migraine headache and vascular diseases.... Agent: Arent Fox PLLC

20070060587 - Indane derivates as muscarinic receptor agonists: The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.... Agent: Eli Lilly & Company

20070060588 - Fused bicycloheterocycle substituted quinuclidine derivatives: wherein n is 0, 1, or 2; A is N or N+—O−; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed... Agent: Robert Deberardine Abbott Laboratories

20070060590 - 6-membered heterocyclic compound and use thereof: [T represents oxygen atom and the like; V represents CH2 and the like; RO1 to RO4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents... Agent: Birch Stewart Kolasch & Birch

20070060589 - Inhibitors of protein arginine methyl transferases:

20070060591 - Chemokine receptor binding heterocyclic compounds: The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors... Agent: Morrison & Foerster LLP

20070060592 - Chemokine receptor antagonists and methods of use therefor: e

20070060593 - 4-carboxamido quinoline derivatives for use as nk-2 and nk-3:

20070060594 - Pyridinyl acetonitriles: The present invention is related to pyridinyl acetonitriles as well as to pharmaceutical formulations containing such pyridinyl acetonitriles. Said pyridinyl acetonitriles are modulators of the protein kinase signalling pathways, particularly the one involving Glycogen Kinase Synthase 3 or JNK. The present invention is furthermore related to methods of preparing pyridinyl... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070060595 - Novel fused heterocyclic compound and use thereof: wherein, a fused ring AB represents a 5- to 10-membered fused heterocyclic ring; R1 represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxyl group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8)... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070060597 - Crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-n-[(1s)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts: The present invention relates to crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts; processes for the production thereof; pharmaceutical compositions thereof; and methods for inhibiting tumor growth therewith.... Agent: Wilmerhale/wyeth

20070060596 - Heterocyclyl compounds: e

20070060598 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition,... Agent: Jones Day

20070060599 - Crystalline forms of [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one: e

20070060601 - Mitotic kinesin inhibitors: The present invention relates to 2,3-diarylquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20070060600 - 4-anilinequinazolines with adenosine-kiase inhibitor properties: The present invention relates to the use of 4-anilinoquinazoline derivatives as adenosine-kinase inhibitors. The present invention also relates to a method for protecting tissues and organs like heart, brain and kidneys affected by ischemia, and for treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery restenosis after angioplasty,... Agent: Trask Britt

20070060602 - Triaza-cyclopenta [cd] indene derivatives: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence,... Agent: Sughrue Mion, PLLC

20070060603 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic... Agent: Dechert LLP

20070060604 - Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment: The present invention relates to pharmaceutical composition with lysergol as bioactive enhancer and bioavailability facilitator for broad-spectrum antibiotics. The present invention has direct implication in reducing the dosage of antibiotics while increasing the efficiency of absorption of nutritional elements.... Agent: Buchanan, Ingersoll & Rooney PC

20070060605 - Compositions and methods for inhibiting platelet activation and thrombosis: The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation. The... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070060606 - Compounds and methods for modulating phosphodiesterase 10a: Novel compounds that modulate PDE10A, a gene that is primarily expressed in medium spiny neurons of the mammalian striatum and has been found to inhibit striatal output by reducing spiny medium excitability and effect cAMP and cGMP signalling cascades in vivo in rats, and methods for treating psychosis and schizophrenia... Agent: Bromberg & Sunstein LLP

20070060607 - 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives: v

20070060608 - Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds: A composition, method and kit comprising a compound for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin and other therapeutic compounds for the control or prevention of diseases states in which α4β1 is involved.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070060609 - Identification and use of growth hormone secretagogue receptor type 1a antagonists: Compounds that are ligands for the growth hormone secretagogue receptor type 1A (GHS-R 1A), as well as pharmaceutically acceptable salts of such compounds, are useful for the manufacture of medicaments for the regulation of food intake.... Agent: Novo Nordisk, Inc. Patent Department

20070060610 - Methods and pharmaceutical formulations for increasing bioavailability: This invention relates to methods and compositions for increasing the bioavailability of pharmaceutical or lipophilic compounds. The invention further relates of methods of administering the compounds and compositions of the present invention to a human or animal.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070060611 - Method of treating or inhibiting the development of brain inflammation and sepsis: A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070060612 - Antitumor agents: wherein Y is F, Cl or Br; or a pharmaceutically acceptable salt thereof. The compounds are effective antitumor agents. The invention also provides pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering a... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070060613 - Met kinase inhibitors: The present invention is directed to compounds that are useful for treating cancer having one of the following Formulas:... Agent: Louis J. Wille Bristol-myers Squibb Company

20070060614 - Methods of treating cancer with hdac inhibitors: The present invention relates to methods of treating cancers, e.g., mesothelioma or lymphoma. More specifically, the present invention relates to methods of treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20070060615 - Method of modulating apoptosis through modulation of e2f1: Provided is a method and vector for modulating apoptosis in a target cell population. Flavopiridol treatment leads to apoptosis via a mechanism associated with downregulation of Mcl-1. E2F1 leads to transcriptional repression of Mcl-1 and subsequently apoptosis. Given the ability of cyclin/cyclin-dependent kinase 2 antagonists to kill transformed cells, flavopiridol... Agent: Smith Hopen, Pa

20070060616 - Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds: This invention is generally directed to the use of Indazole Compounds for treating or preventing chronic lymphocytic leukemia. The methods comprise the treatment or prevention of chronic lymphocytic leukemia comprising administering an effective amount of an indazole compound, or a pharmaceutically acceptable salt or composition thereof, to a patient in... Agent: Jones Day

20070060617 - 2-methoxy-5(5-trifluoromethyl-tetrazol-1-yl-benzyl)-2s-phenyl-piperdin-3s-yl)-amine for the treatment of social phobia: The present invention provides the a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof or pharmaceutical compositions containing the same for the treatment of social phobia (otherwise known as Social Anxiety Disorder).... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070060618 - Alkyne derivatives as tracers for metabotropic glutamate receptor binding: The present invention is directed to isotopically labeled alkyne derivative compounds, particularly 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled compounds. In particular, the present invention is directed to 11C, 13C, 14C, 18F, 15O, 13N, 35S, 2H, and 3H labeled heterocyclic alkynes and methods of their preparation.... Agent: Merck And Co., Inc

20070060619 - Nicotinamide-based kinase inhibitors: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating tyrosine kinase-associated disease states in a subject using a compound of formula (I) is also described.... Agent: Morrison & Foerster LLP

20070060620 - Use of rar retinoid agonists to increase sperm count and sperm mobility in males: The present invention provides a method for treating infertility which may be caused by sperm immobility, comprising administering to a person in need of treatment for infertility an effective amount of a pharmaceutical composition comprising a RAR retinoid selective compound to activate sperm motility, together with a pharmaceutically acceptable excipient,... Agent: Robert J. Baran Allergan, Inc.

20070060622 - Compositions and methods using proton pump inhibitors: The invention provides methods for treating and preventing cystic fibrosis, radiation therapy-induced emesis, chronic ear infections, bruxism, motion sickness, tooth decay due to emesis and other disorders by administering to a patient a therapeutically effective amount of at least one proton pump inhibitor. In other embodiments, the proton pump inhibitor... Agent: Lahive & Cockfield, LLP

20070060621 - Methods and compositions for the administration of prodrugs of proton pump inhibitors: Disclosed herein are methods, compositions, and dosage forms related to prodrugs of a proton pump inhibitors wherein said compositions and dosage forms do not comprise a salt of phosphoric acid. Principles related to the use of various anions and buffers in relation to these prodrugs are also disclosed.... Agent: Allergan, Inc.

20070060623 - Acid secretion inhibitor: wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle optionally has substituent(s), R2 is an optionally substituted C6-14 aryl group, an optionally substituted thienyl group or an optionally... Agent: Edwards & Angell, LLP

20070060625 - Methods of modulating intestinal fluid balance: The present invention relates to methods for treating or preventing intestinal fluid balance disorders and modulating intestinal fluid secretion and absorption using calcimimetics and calcilytics.... Agent: Amgen Inc.

20070060624 - Novel bioisosteres of actinonin: The present invention relates to novel bioisosteres of the antibiotic actinonin of the general formula (I). The novel compounds are of particular interest as inhibitors of metalloproteinases.... Agent: Edwards & Angell, LLP

20070060626 - 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof: e

20070060627 - Organic compounds: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.... Agent: Novartis Corporate Intellectual Property

20070060628 - Therapeutic agent for keratoconjunctival disorder: Object of the present invention is to search a novel pharmaceutical use of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2, 4-dione being a condensed heterocyclic compound, or a salt thereof. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl] thiazolidine-2, 4-dione or a salt thereof can exert an excellent effect to promote healing in a dry eye model, and is useful... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070060629 - Large conductance calcium-activated k channel opener: wherein R1 and R3 are each sulfonamide, carbamoyl, acyl, amino, and the like, m and n are each 0 to 2, R2 and R4 are each cyano, nitro, hydroxyl, an alkoxy, a halogen, or an alkyl, Ring A is benzene or a heterocyclic ring, Ring B is benzene, a heterocyclic... Agent: Birch Stewart Kolasch & Birch

20070060630 - Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same: e

20070060631 - Tetrazole fungicides:

20070060632 - Lofexidine: The present invention provides a method for treating a patient in need of analgesia comprising administering intraspinally to said patient an effective amount of lofexidine or a pharmaceutically acceptable salt thereof.... Agent: Nixon & Vanderhye, PC

20070060633 - Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof: wherein R1, R2, R3, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070060634 - Compounds and compositions to control abnormal cell growth: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight,... Agent: Faegre & Benson LLP Patent Docketing

20070060635 - Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070060637 - Anti-cancer combinations: The present invention relates to synergistic combinations of the compound 5,6 -dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20070060636 - High enantiomeric purity dexanabinol for pharmaceutical compositions: The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and... Agent: Winston & Strawn LLP Patent Department

20070060639 - Compositions and methods for intranasal delivery of tricyclic cannabinoids: A pharmaceutical composition for intranasal administration to a human or non-human subject is provided, comprising a therapeutically active component that comprises at least one tricyclic cannabinoid in a liquid to semi-solid medium that comprises a pharmaceutically acceptable solubilizing agent in an amount effective to solubilize the cannabinoid. An amount of... Agent: Harness, Dickey, & Pierce, P.l.c

20070060638 - Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist: Combination therapies of a cannabinoid receptor agonist and a cannabinoid antagonist in an amount effective to potentiate, but not antagonize, the therapeutic effect of the cannabinoid receptor agonist are provided. Also provided are methods for use of these combination therapies in potentiating a therapeutic effect of cannabinoid receptor agonists, inhibiting... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.C.

20070060640 - Antiarrhythmic precursor compounds, methods of synthesis and methods of use: wherein, R1 is independently H or halogen; R2 is, for example, H or —R10—NR11R12, and wherein R10 is C1-C6 alkyl, and R11 and R12 are independently H, C1-C4 alkyl, and hydrates, solvates, salts and tautomers thereof. The invention further comprises methods for making the compounds of the invention and methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070060641 - Therapeutic agent: The present invention relates to a therapeutic agent or prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an insulin-mimetic action agent, a food, beverage, or feed, an agent for enhancement of glucose uptake into a cell, and an agent for inducing differentiation... Agent: Birch Stewart Kolasch & Birch

20070060642 - Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate: The present invention relates to a process for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate as well as intermediates for use in said process. More in particular the invention relates to processes for the preparation of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate which make use of 4-amino-N-((2R,3S)-3-amino-2-hydroxy-4-phenylbutyl)-N-(isobutyl)benzene sulfonamide intermediate, and to processes amenable to... Agent: Philip S. Johnson Johnson & Johnson

20070060643 - Autoinducer compounds: Autoinducer compounds which enhance gene expression in a wide variety of microorganisms, therapeutic compositions and therapeutic methods wherein gene expression within microorganisms is regulated are disclosed.... Agent: Lahive & Cockfield, LLP

20070060644 - Therapeutic curcumin derivatives: Curcumin analogues and methods are provided for treatment of disease.... Agent: Mueting, Raasch & Gebhardt, P.A.

20070060645 - Purification of cinacalcet: Isolated cinacalcet carbamate, processes for the preparation thereof, and processes for the use of cinacalcet carbamate as a reference marker and standard are provided. Also provided are cinacalcet salts substantially free of cinacalcet carbamate, and processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20070060646 - Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction: The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of... Agent: Millen, White, Zelano & Branigan, P.C.

20070060647 - Gene expression regulating agent: An object of the invention is to provide a gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester. Abnormal gene expression due to, for example, oxidative stress... Agent: Venable LLP

20070060648 - Lipids from methanotrophic bacteria for cholesterol reduction: The present invention provides the use of lipids from methanotrophic bacteria for the manufacture of a composition for oral administration for use in the treatment of animal subjects to reduce plasma cholesterol levels therein or to reduce the ratio of LDL to HDL cholesterol in the plasma thereof. The composition... Agent: Sughrue Mion, PLLC

20070060649 - Novel lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives: The present invention is directed to a novel lysine salts, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by PPAR delta. The present invention is further directed to a novel process for the preparation of said lysine salts,... Agent: Philip S. Johnson Johnson & Johnson

20070060650 - Solid skin care composition comprising multiple layers: The present invention relates to a solid skin care composition comprising: (a) a first layer which is solid at 45° C. and which is a water-in-oil emulsion; and (b) a second layer which is solid at 45 ° C. and which is an oil-in-water emulsion comprising a benefit agent; wherein... Agent: The Procter & Gamble Company Intellectual Property Division

20070060651 - Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia: Compositions and methods for enhancing vascular integrity in animals are disclosed. The compositions and methods, which utilize long chain polyunsaturated fatty acids and nitric oxide releasing compounds are also effective for reducing ischemia-induced brain injury in an animal.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070060652 - Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in... Agent: Alston & Bird LLP

20070060653 - Physiologic vaginal lubrication to optimize sperm survival and function: A topical application of a preparation of menthol, or a related cooling compound, and L-arginine to the female clitoris, a reflex normal physiological vaginal lubrication can be induced. This physiological vaginal lubrication provides optimum support for spermatozoa survival and function within the female reproductive tract, specifically in the vagina and... Agent: Donald N. Halgren

20070060654 - Association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it: Association comprising agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in association with a noradrenaline reuptake inhibitor agent. Medicinal products containing the same which are useful in treating conditions associated with mood disorders.... Agent: The Firm Of Hueschen And Sage

20070060655 - Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient.... Agent: The Firm Of Hueschen And Sage

20070060656 - Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for producing thereof: e

20070054838 - Method for improving diagnostic quality in echocardiography: The present invention provides a method for improving diagnostic quality in echocardiography, especially for patients having an elevated heart rate.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070054839 - Method of inhibiting remnant lipoprotein production: The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory... Agent: Leydig Voit & Mayer, Ltd

20070054841 - Method of treatment of systemic injury secondary to burns: The invention relates to the prevention or treatment of a systemic injury which is secondary to a burn, such as dysfunction or failure of an organ secondary to a burn, with an antagonist of a C5a receptor. In one embodiment the invention relates to the prevention or treatment of dysfunction... Agent: Haynes And Boone, LLP

20070054843 - Methods for treatment of headaches by administration of oxytocin: The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.... Agent: Morrison & Foerster LLP

20070054842 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering... Agent: Knobbe Martens Olson & Bear LLP

20070054840 - Template-fixed peptidomimetics with antimicrobial activity: Template-fixed β-hairpin peptidomimetics of the general formula (I), wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly or Pro, or of certain types, at least one of these residues being of... Agent: Hoffmann & Baron, LLP

20070054844 - Method for treating otitis externa: This invention relates to a method of treating otitis externa using a topical combination medication, including one or more antifungal agent such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin, micafungin, terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z,... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20070054846 - Bcl-w structure and uses therefor: The present invention discloses the solution structure of Bcl-w and Bcl-w complexes as well as methods of using that structural information to screen for and design compounds that interact with Bcl-w or variants thereof.... Agent: Knobbe Martens Olson & Bear LLP

20070054848 - Composition and method for nerve regeneration: The present invention provides a pharmaceutical composition and method for regenerating nerves and treating neurological diseases based on nerve regeneration. The present invention employs a substance, such as Pep5, PKC, IP3, Rho, Rho GDI, Rho kinase, or the like, which are involved in a p75 signal transduction pathway, or an... Agent: Perkins Coie LLP

20070054853 - Composition and method for treatment and prevention of restenosis: Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of... Agent: Conley Rose, P.c.

20070054852 - Compositions and methods of use of semaphorin 3f and antagonists thereof in the stimulation of neuromuscular regeneration and treatment of muscular diseases: The present invention relates to therapeutic uses of Semaphorin 3F or related proteins. The therapeutic uses include methods of using Semaphorin 3F compounds alone, or in conjunction with other agents, for the stimulation of neuromuscular regeneration, and the treatment of diseases or conditions characterized by muscle denervation and muscle atrophy.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070054856 - Compositions and methods of using angiopoietin-like 4 protein: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.... Agent: Heller Ehrman LLP

20070054859 - Estrogen receptor-related receptor alpha (erralpha) and cartilage formation: Estrogen related receptor α (ERRα) is involved in control of cartilage formation in mammals. Increasing ERRα activity causes stimulation of cartilage formation, providing a means of therapeutic intervention in diseases such as arthritis which involve cartilage destruction. Compounds may be screened for their potential as therapeutics by screening their effect... Agent: Myers Bigel Sibley & Sajovec

20070054845 - Fragments of the human zn-alpha2-glycoprotein and their use in methods of treatment of obesity: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GZIP polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070054849 - Method for diagnosing hepatocellular carcinomas: Objective methods for detecting, diagnosing, treating and preventing hepatocellular carcinoma (HCC) are described herein. In particular, the present invention relates to two genes up-regulated in HCC cells as compared to normal cells, referred to herein as MGC47816 and HES6. In one embodiment, the diagnostic method involves the determining the expression... Agent: Townsend And Townsend And Crew, LLP

20070054858 - Method of treating hepatocellular carcinoma: Materials and methods for treating hepatocellular carcinoma in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070054851 - Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases: The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070054854 - Methods of using retro-inverso peptides derived from interleukin-3: The invention provides methods of treatment using retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. These peptides of the invention have the same activity as native IL-3 and also have... Agent: Kenyon & Kenyon LLP

20070054857 - Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof: The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average... Agent: Cooper & Dunham, LLP

20070054855 - Modified annexin proteins and methods for their use in organ transplantation and in prevention of thrombosis and reperfusion injury: Modified annexin proteins, including a homodimer of human annexin V, are provided. Methods for their use, such as to prevent thrombosis without increasing hemorrhage and to attenuate ischemia-reperfusion injury (IPI), are also provided. The modified annexins bind phosphatidylserine (PS) on cell surfaces, thereby preventing the assembly of the prothromkinase complex.... Agent: Swanson & Bratschun L.l.c.

20070054850 - Screening method: The present inventors have found that relaxin-3 has a feeding-stimulating activity, a body weight increasing activity, and fat weight increasing activity by intracerebroventricularly administering relaxin-3 to rats and observing the amount of feeding, body weight and fat weight, and so on after the administration. According to the present invention, a... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070054861 - Therapeutic uses of smr1 peptides: The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.c.

20070054860 - Treatment of ischemic events: The invention relates to the treatment of an ischemic event such as a stroke or myocardial infarction. The invention provides a method for modulating an ischemic event in a subject comprising providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides use of an NF-κB-down-regulating... Agent: Trask Britt

20070054847 - Use of adnf polypeptides for treating anxiety and depression: This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of... Agent: Townsend And Townsend And Crew, LLP

20070054862 - Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing an adenosine kinase: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and... Agent: Dechert LLP

20070054863 - Compounds that regulate apoptosis: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that... Agent: Knobbe Martens Olson & Bear LLP

20070054865 - Anti-inflammatory peptides: X1-X2-X3 wherein X1 is selected from the group consisting of 2-amino-hexanoic acid; 2-amino-heptanoic acid; 2-amino-octanoic acid; cyclohexyl-substituted 2-amino-ethanoic acid, 2-amino-propanoic acid or 2-amino-butanoic acid and methionine; X2 is an acidic amino acid; and X3 is an aliphatic amino acid; or of a peptide of the formula: X4-X5 wherein X4 is... Agent: Myers Bigel Sibley & Sajovec

20070054864 - Hcv inhibitors: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20070054866 - Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation: The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070054867 - Crystalline forms of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments: The invention relates to a crystalline hydrate of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and to crystalline complexes between 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene and a natural amino acid, to methods for the preparation thereof, as well as to uses thereof for preparing medicaments.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070054868 - Synergistic polyphenol compounds, compositions thereof, and uses thereof: The present invention relates to Synergistic Polyphenol Compounds, compositions thereof, and methods for treating or preventing cancer in a subject, the methods comprising administering to a subject an effective amount of a Synergistic Polyphenol Compound or composition thereof.... Agent: Wilmerhale/columbia University

20070054869 - Antisense modulation of superoxide dismutase 1, soluble expression: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of... Agent: Knobbe, Martens, Olson & Bear, LLP

20070054870 - Heterobifunctional pan-selectin inhibitors: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a... Agent: Seed Intellectual Property Law Group Pllc

20070054873 - Glucocorticoid modulation of nucleic acid-mediated immune stimulation: The present invention provides methods for minimizing or inhibiting immune responses to immunostimulatory nucleic acids by pretreating with one or more doses of a glucocorticoid prior to nucleic acid administration. The nucleic acids are typically administered using a lipid-based carrier system such as a nucleic acid-lipid particle or liposome. As... Agent: Townsend And Townsend And Crew, LLP

20070054871 - Method and apparatus for device controlled gene expression for cardiac protection: A gene regulatory system detects ischemia events and is capable of delivering a biologic therapy in response to the detection of an ischemic event or the reception of a command. The biologic therapy protects the heart from ischemic damage by regulating the expression of an exogenously introduced gene product. In... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20070054872 - Regulatable or conditional expression systems: Endogenous gene regulation mechanisms together with microRNAs expressed in many organisms can be used to provide regulated or conditional expression of transgenes by placing an appropriate sequence, a microRNA binding site, within the transcribed gene. This microRNA-dependent transcription regulation can be further regulated using microRNA inhibitors.... Agent: Mirus Corporation

20070054875 - L-nucleosides as ligands to adenosine receptors: Disclosed herein are compounds having Formula I, which are non-natural L-adenosine analogs. Also disclosed are their methods of making. Still further, disclosed are the uses of the disclosed compounds to treat cardiovascular disease, ischemia related injuries, and neurodegenerative diseases.... Agent: Needle & Rosenberg, P.c.

20070054874 - Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis: Disclosed are clinical methods for inducing apoptosis selectively in tumor cells while sparing normal cells. These methods employ drugs that, acting alone or in synergistic combinations, produce an increase in intracellular Calcium loading such that either or both of two major apoptotic pathways are triggered to produce selective killing of... Agent: Swanson & Bratschun L.l.c.

20070054876 - Pharmaceutical composition promoting defecation: The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine A2 receptor antagonism, preferably an adenosine A2b receptor antagonism, or a salt thereof.... Agent: Birch Stewart Kolasch & Birch

20070054877 - Antiadhesive carbohydrates: Provided is a pharmaceutical or dietetic product, which serves for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, in particular mammal cells. Said preparation contains at least one carbohydrate having an uronic acid unit on one of the ends thereof. 10 to 100% of the... Agent: Bacon & Thomas, Pllc

20070054878 - Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis: Rheumatoid arthritis is a chronic inflammatory disease, leading to joint destruction. Conventional therapy is based on pain-reduction and an improvement in the frictional properties of joints, in order to delay the time for operative intervention. A lack of specifically-acting agents for drug-based therapy for arthritis exists. The formulations comprise sulphated... Agent: Jacobson Holman Pllc

20070054879 - Beta-chitin complex and method for producing the same: The present invention provides a β-chitin complex composed of an inclusion compound formed by using a β-chitin as a host and a guest compound which is a compound having a functional group that can form a hydrogen bond with a hydroxyl group and/or an amide group of the β-chitin and... Agent: Le-nhung Mcleland

20070054880 - Cellulose oxidation by nitrogen dioxide in a perfluorinated tertiary amine solvent: This invention relates to a process for preparing bioabsorbable oxidized cellulose comprising combining cellulose material, with nitrogen dioxide and a nonaqueous solvent chosen from the class of perfluorinated tertiary amines. This invention also relates to a method of oxidizing cellulose material comprising introducing a solvent into the vessel, circulating the... Agent: Foley And Lardner LLP Suite 500

20070054881 - Anxiolytic agents with reduced sedative and ataxic effects: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.... Agent: Wisys Technology Foundation, Inc. C/o Mirick, O'connell, Demallie & Lougee, LLP

20070054882 - Male anti-fertility agents: Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20070054884 - 4-substituted 2-aryloxyphenol derivatives as antibacterial agents: Antimicrobial compounds, compositions and methods of treatment administering same, of 2-aryloxyphenol derivatives having heterocyclic groups or highly polar functional groups substituted at position 4 of the phenolic ring, as well as methods for their preparation and formation, wherein the compounds are generally of Formula 1.... Agent: Foley And Lardner LLP Suite 500

20070054883 - Anti-bacterial agents based upon oxoanion binding: are useful for treating bacterial growth, wherein E is selected from the group consisting of B, P, and S, T1, and T2 are each independently selected from the group consisting of O, NR, and CH2, where R=H or C1-C8 alkyl, or C1-C8 oxoalkyl, and L is selected from the group... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20070054885 - Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases: A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-lyl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.... Agent: Novartis Corporate Intellectual Property

20070054886 - Ras antagonists for treating neurodegenerative disorders: Disclosed are methods of neuroprotection or treatment of neurodegenerative disorders with Ras antagonists.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070054887 - Methods for treating bladder dysfunction: There is provided according to the invention the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epi-cholecalciferol in the prevention or treatment of bladder dysfunction.... Agent: Edwards & Angell, LLP

20070054888 - Novel substituted diamine derivatives useful as motilin agonists: wherein R1, R2, R3, R4, X1, X2, X3, X4, A, Y and n are as described in the specification, pharmaceutical compositions containing them and intermediates used in their manufacture. More particularly, the compounds of the invention are motilin receptor antagonists useful for the treatment of associated conditions and disorders such... Agent: Philip S. Johnson Johnson & Johnson

20070054889 - Injectable sterile pharmaceutical formulation containing at least two active principles: Mixtures of at least two active principles, of which at least one is the sodium salt, are precipitated from an organic solution containing the same active principles in salified or non-salified acid form.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.c.

20070054890 - Protein synthesis required for long-term memory is induced by pkc activation on days preceding associative learning: The present invention provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070054891 - Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formula (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at... Agent: Banner & Witcoff

20070054892 - Isoquinoline potassium channel inhibitors: The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20070054893 - Prostaglandin analogs: e

20070054894 - Quinazoline potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20070054895 - 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents: e

20070054896 - Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20070054897 - Heteroaryl-ureas and their use as glucokinase activators: e

20070054898 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same:

20070054899 - Aromatase inhibitor compounds and uses thereof: The invention concerns the use of a compound of formula (I) inhibitor of aromatase for the preparation of a pharmaceutical formulation intended for treatment of cancer or psoriasis. It equally relates to compounds of formula (I), notably for their use as active ingredients of a medication.... Agent: Fulbright & Jaworski L.l.p.

20070054900 - 4-phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy: The invention relates to novel derivatives of 4-phenylthiazoles and 4-phenylimidazoles and the use thereof medicament. The invention especially relates to the following compounds: butyl-2-[4-(4-(aminophenyl)-1<i>H</i>-imidazol-2-yl]ethyl-carbamate, and 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, and the salts of the same.... Agent: Hunton & Williams LLP Intellectual Property Department

20070054901 - Dihydrothiazine prodrugs of thiazolium agents: R1 and R2 are independently selected from hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C3-C8 cycloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, amino, monoalkylamino, dialkylaminoalkyl, and pyrrolidin-1-ylalkyl; and Y is selected from the group consisting of C1-C6 alkyl, substituted and unsubstituted aryl; with the provisos that: (a) if Y is aryl, then at least... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.

20070054902 - Isoxazole derivatives as peroxisome proliferator-activated receptors agonists: R1-R10 are each independently hydrogen, halogen, optionally substituted lower alkyl or the like, X1 is —O—, —S—, —NR11— (wherein R11 is hydrogen, lower alkyl or the like), —CR12R13CO—, —(CR12R13)mO—, —O(CR12R13)m- (wherein R12 and R13 are each independently hydrogen or lower alkyl and m is a integer between 1 and 3)... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070054903 - Bis-aryl kinase inhibitors and method: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20070054904 - Phenol derivatives and their use as rotamase inhibitors: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and —S(O2)—NR14—, —O—, —S— or are each and individually absent; X... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20070054906 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070054905 - Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process: The invention relates to indole-derived compounds and to the use of said compounds for the preparation of a medicament that can be used to treat diseases related to the process of splicing pre-messenger RNAs in the cell, such as Frasier syndrome, frontotemporal dementia linked to chromonsoem 17 (a form of... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20070054907 - Novel modulators of the ppar-type receptors and pharmaceutical/cosmetic applications thereof: e

20070054908 - Novel pharmaceutical compositions and methods for treating tumors, including drug-resistant tumors: Pharmaceutical compositions comprising a chemotherapeutic agent comprising one of the previously unknown antineoplastic agents, DL-001 or DL-002 and methods for inhibiting tumor cell proliferation, inducing tumor cell death by apoptosis and inhibiting growth of a drug resistant tumor comprising administration of the inventive compositions are provided. Successfully treated tumors include... Agent: Dinsmore & Shohl, LLP

20070054909 - Vla-4 inhibitor compounds: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are... Agent: Heslin Rothenberg Farley & Mesiti Pc

20070054911 - Muscarinic modulators: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone

20070054910 - Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods: This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount... Agent: Patent Docket Administrator Lowenstein Sandler Pc

20070054912 - Modulators of acetylcholine receptors: Compounds comprising an aza-bicyclic portion and an aromatic portion linked via an optionally oxidized sulphur atom are disclosed. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.... Agent: Merck And Co., Inc

20070054913 - 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands: m

20070054914 - Eszopiclone process: Eszopiclone is prepared by reacting zopiclone with an enatiomerically pure di-p-toluoyl tartaric acid, recovering a solid salt, and reacting a solid salt with a base. Zopiclone is prepared by reacting 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]-pyrazine with 1-chlorocarbonyl-4-methylpiperazine hydrochloride.... Agent: Dr. Reddy's Laboratories, Inc.

20070054915 - P38 map kinase inhibitors and methods for using the same: z

20070054916 - Aryl nitrogen-containing bicyclic compounds and methods of use: wherein A1, A2, A3, B, R1, R2, R3 and R4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for... Agent: Amgen Inc.

20070054917 - Piperazine derivates and their use for the treatment of neurological and psychiatric diseases: The present invention relates to novel piperidine carbonyl piperazine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070054918 - N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor: The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Ra which is/are selected, independently of each other, from halogen, CN, NO2,... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070054920 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: e

20070054919 - Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070054922 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: d

20070054921 - Substituted indoles and a process for preparing substituted indoles: The instant invention is directed to novel compounds of Formulae (I) and (II), as wells a process for preparing compounds of Formula (II). The process comprises a palladium-catalyzed reductive cyclization of a compound of Formula (I) to produce a compound of Formula (II).... Agent: Merck And Co., Inc

20070054923 - Inhibitors of macrophage migration inhibitory factor and methods for identifying the same: e

20070054924 - Novel piperidines as chemokine modulators (ccr):

20070054925 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070054926 - Fungicidal mixtures:

20070054927 - Fungicidal mixtures:

20070054928 - C-met modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Leydig Voit & Mayer, Ltd

20070054929 - 2-substituted pyrimidines: e

20070054930 - Cxcr4 antagonists for the treatment of medical disorders: The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating... Agent: King & Spalding LLP

20070054931 - Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof: e

20070054932 - Inhibitors of abc drug transporters at the blood-brain barrier: The present invention relates to inhibitors of drug transporters of the ABC protein superfamily, particularly transporters present at the blood brain barrier. ABC transporter inhibitors identified according to the invention increase brain concentrations of CNS-active agents. Such inhibitors increase the influx into the brain and/or reduce the efflux from the... Agent: Bell, Boyd & Lloyd, Llc

20070054933 - 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20070054934 - Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent: The present invention relates to a new association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent.... Agent: The Firm Of Hueschen And Sage

20070054935 - Novel pyridine derivatives as potassium ion channel openers: The present invention is directed to novel pyridine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels.... Agent: Philip S. Johnson Johnson & Johnson

20070054937 - Method of treating or inhibiting the development of brain inflammation and sepsis: A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070054936 - Novel quinoline derivatives as potassium ion channel openers: The present invention is directed to novel quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels.... Agent: Philip S. Johnson Johnson & Johnson

20070054938 - Antitumor agents: wherein Y is F, Cl or Br; or a pharmaceutically acceptable salt thereof. The compounds are effective antitumor agents. The invention also provides pharmaceutical compositions comprising a compound of formula I or a salt thereof, intermediates useful for preparing a compound of formula I, and therapeutic methods comprising administering a... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20070054939 - Thiazolypiperidine derivatives as mtp inhibitors: and R1, R2, R2′, R3, R4, R5, Y and Z are as defined in the description. Application of the compounds of the formula (I) to the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia.... Agent: Millen, White, Zelano & Branigan, P.c.

20070054940 - Remedy for down's syndrome: Because there is no fundamental treatment for Down's syndrome, and participation in society is the ultimate goal, the present invention provides a remedy and method for treating Down's syndrome that improve congenital delayed psychomotor development, and promote improvement in the performance of daily activities and socialization. The present invention is... Agent: Birch Stewart Kolasch & Birch

20070054941 - Removal of aldehyde impurity by reactive polystyrene resini: A purification method in the preparation of a substituted 8-arylquinoline, wherein the aryl group at the 8-position contains a substituent substituted-alkenyl group, utilizes a polystyrene-based sulfonylhydrazine reactive resin to remove an aldehyde impurity.... Agent: Merck And Co., Inc

20070054942 - Fused heteroaryl derivatives and their use as p38 kinase inhibitors: p

20070054943 - Therapeutic agent for keratoconjunctival disorder: An object of the present invention is to search a new medicinal use of 5-[p-[2-(methyl-2-pyridylamino) ethoxy]benzyl]-2,4-thiazolidinedione and 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione. 5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione or a salt thereof exerts an excellent improving effect on corneal disorder models, therefore, it is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20070054944 - Pharmaceutical compositions comprising 1-isopropyl-3-[ (4-m-toluidino-3-pyridyl) sulphonyl] -urea as active ingredient: The present invention concerns the use of 1-isopropyl-3-[(4-m-toluidino-3-pyridyl)sulphonyl]-urea in the pharmaceutical field. In particular, it proposes the use of a pure and stable polymorphic form of 1-isopropyl-3-[(4-m-toluidino-3-pyridyl)sulphonyl]-urea for the preparation of solid pharmaceutical forms, and likewise a method of synthesis to obtain such a pure and stable polymorphic form of... Agent: Mayer, Brown, Rowe & Maw LLP

20070054945 - Acyloxyalkyl carbamate prodrugs, methods of synthesis and use: The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (±)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders... Agent: Dorsey & Whitney LLP

20070054946 - Novel indeno[2,1a]indenes and isoindolo[2,1-a]indoles: The invention also provides a method to prepare the compound of formula I, pharmaceutical composition containing such compounds, and method to manufacture a medicament. These compounds are useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardio vascular diseases... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20070054949 - Compositions comprising novel ppar ligands and anti-hyperlipemic agents: Methods are provided for treating or preventing conditions comprising hypertension and dyslipidemia using antihyperlipemic agents and compounds that antagonize the angiotensin II type 1 (AT1) receptor, function as partial or full activators of peroxisome proliferator activated receptors (PPARs) and lower triglycerides or elevate blood HDL-cholesterol. Compositions are provided for treating... Agent: Morrison & Foerster LLP

20070054947 - Pharmaceutical composition comprising valsartan: The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in... Agent: Novartis Corporate Intellectual Property

20070054948 - Purification of olmesartan medoxomil: The present invention provides a process for purifying olmesartan medoxomil. Also provided is pure olmesartan medoxomil.... Agent: Kenyon & Kenyon LLP

20070054950 - 3-azabicyclo[3.1.0]hexane derivatives: e

20070054952 - Anti-inflammatory analgesic for external use: An objective of the present invention is to provide an anti-inflammatory analgesic for external use comprising etodolac as NSAID. The anti-inflammatory analgesic for external use is excellent not only in skin permeability but also in penetratability and diffusivity into tissues present in portions deeper than the skin, can act directly... Agent: Wenderoth, Lind & Ponack, L.l.p.

20070054951 - Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists: Novel cycloalkanoindole derivatives of formula (I) are antagonists of prostaglandins, and as such are useful for the treatment of prostaglandin mediated diseases.... Agent: Merck And Co., Inc

20070054953 - A novel process for preparation of indole derivatives: A novel process of preparation of a compound of 3-(2-Dimethylamino)-N-methyl-1H-indole-5-methane sulfonamide, which comprises of a reaction 4-hydrazino-N-methyl benzene methane sulfonamide with 4-dimethyl amino butyraldehyde diethyl acetal in a chlorinated solvent in the presence of ethyl poly phosphate and conversion of the crude product to a product of 3-(2-Dimethylamino)-N-methyl-1H-indole-5-methane sulfonamide succinate... Agent: Ramesh Babu Vishwanath Vishwanath & Company

20070054954 - Method of manufacturing glimepiride and the respective intermediate: A method of manufacturing glimepiride of formula I wherein trans-4-methylcyclohexylamine pivalate of formula VII is reacted, either directly or after conversion to trans-4-methylcyclohexylamine or to its another salt, with an alkyl [4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1 yl)carbonyl]amino)ethyl)phenyl]-sulfonyl carbamate of general formula IV wherein R is a C1-C5 alkyl, giving glimepiride of formula I. trans-4-Methylcyclohexylamine... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.c.

20070054955 - Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics.: The invention relates to novel 5-thioxylose compounds, preferably derivatives of the 5-thioxylopyranose type, to the method for their preparation and to their use as active principles of drugs intended especially for the treatment or prevention of thromboses or cardiac insufficiency.... Agent: Merchant & Gould Pc

20070054956 - Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators: The present invention provides a compound of the formula (I) wherein R is —H, or —C1-C4 alkyl; R1 is —H, —OH, —O(C1-C4 alkyl), —SO2(C1-C4 alkyl), or halo; X is —O—, —CH2—, or —C(O)—; X1 is —O— or —NR2—; R2 is —H or —CH3; Y is —S—, —CH2CH2—, or —HC═CH—; m... Agent: Eli Lilly & Company

20070054957 - Stable oxaliplatin formulation: A storage stable pharmaceutical composition comprising a solution of Oxaliplatin in water and a catalytic amount of a carbohydrate. A process for forming such pharmaceutical composition comprising dissolving a known amount of Oxaliplatin in water; adding an amount of carbohydrate in the range of 0.0010% to 0.05% w/v with respect... Agent: Merchant & Gould Pc

20070054958 - Compounds for treatment of lipase-mediated diseases: Novel benzoquinone-derived compounds and polymorphs, prodrugs, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of such compounds, polymorphs, prodrugs and isomers are provided. Process for preparation of compounds of the invention and pharmaceutical compositions containing such compounds and their use for reducing or inhibiting activity of... Agent: Morrison & Foerster LLP

20070054959 - Dichloric acids, reactive chlorine compounds, their derivatives, anions and salts, as well as processes for their manufacture and use: This invention relates to aqueous solutions of reactive chlorine compounds having the empirical formulae H2Cl2O6 or ClO3H, for example, and the derivatives, anions or salts thereof. The invention further relates to methods for the production of said compounds and the use thereof in the pharmaceutical and particularly in the medical... Agent: Marshall, Gerstein & Borun LLP

20070054960 - Sertraline acid addition salt, its preparation and its use in the preparation of sertraline hydrochloride form ii: The present invention relates to novel acid addition salts of sertraline, their preparation and their use in the preparation of crystalline Form-II of Sertraline hydrochloride.... Agent: Novartis Corporate Intellectual Property

20070054961 - Factor: Provided is a method of producing neurite outgrowth and/or development using RARβ2 and/or an agonist thereof.... Agent: Frommer Lawrence & Haug

20070054962 - Method for treating acute or chronic pain: for treating different types of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary inflammatory osteoarthritic pain. The compounds show an antinociceptive profile and differ from classical analgesics like opioids and non-steroidal... Agent: Harness, Dickey, & Pierce, P.l.c

20070054963 - Amorphous cinacalcet hydrochloride and preparation thereof: Provided is amorphous cinacalcet hydrochloride, processes for the preparation thereof, and pharmaceutical compositions therewith.... Agent: Kenyon & Kenyon LLP

20070054964 - Topical formulations containing o-desmethyl venlafaxine (odv) or its salts: The present invention provides topical compositions comprising O-desmethylvenlafaxine (ODV), a selective serotonin and norepinephrine re-uptake inhibitor, or a pharmaceutically acceptable salt thereof. In certain embodiments, the inventive topical formulations contain one or more percutaneous/permucosal absorption enhancers. Also provided are methods of preparing and using these compositions for the treatment of... Agent: Choate, Hall & Stewart LLP

20070054965 - Ampk activating agent: The present invention relates to provision of AMPK activating agent, endurance enhancing agent, and antifatigue agent, which have rich history of use in foods, high safety, readily available, and high workability, a method of activating AMPK, and a method of preventing, treating and/or ameliorating a life-style-related disease. The present invention... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.c.

20070054966 - Method for preparing novel transcription factors and use: The present invention has an object to develop novel compounds which are effective for the therapy of syndrome X, cancer, myxedema, vascular chronic inflammation and the like, and furthermore prevent/treat the restenosis caused in an artery expansion by a balloon or a stent and have the activity facilitating regenerative medicine... Agent: Birch Stewart Kolasch & Birch

20070054967 - Synergistic mixtures of aromatic alcohols and derivatives thereof and tropolone (derivatives): e

20070049514 - Resonance modulator for diagnosis and therapy: A method and device are disclosed for monitoring and/or altering an immune function. The method uses a resonance modulating compound as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. The resonance modulator has electromagnetic properties that attract immune cells to... Agent: Klarquist Sparkman, LLP

20070049515 - Therapeutic agent for diabetes containing insulin resistance improving agent: A method for treating a disease, in which side effects (for example, edema) are suppressed while maintaining appropriate pharmaceutical effects. The method involves a cycle of administration of the insulin sensitizer wherein the dosage thereof is reduced or withdrawn alternated with administration of an effective dose.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070049516 - Use of insulin for the treatment of cartilaginous disorders: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial,... Agent: Genentech, Inc.

20070049517 - Use of hyperpolymeric hemoglobin for the treatment of pulmonary edema: This invention relates to the use of hypo-oncotic aqueous solutions of molecularly dispersed chemically modified high molecular weight crosslinked hemoglobins, namely so-called hemoglobin hyperpolymers, to prepare agents for the symptomatic, primarily life-saving treatment of acute pulmonary edema. Administration in particular is intravascular. Surprisingly, additive administration can be performed since according... Agent: William Collard Collard & Roe, P.C.

20070049519 - Glycopeptide phosphonate derivatives: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.... Agent: Theravance, Inc.

20070049518 - Novel method of treatment of inflammatory skin conditions: There is provided, inter alia, a method for the treatment or prevention of an inflammatory skin condition which is characterised by colonisation with Staphylococcus aureus, comprising the topical administration of an aureolysin inhibitor.... Agent: Klauber & Jackson

20070049520 - Method of using retro inverso peptides derived from leukemia inhibitory factor: The invention provides methods of treatment using retro-inverso peptides derived from leukemia inhibitory factor (LIF) having between 18 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native LIF and... Agent: Kenyon & Kenyon LLP

20070049530 - Cytokine receptor zcytor17 multimers: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049529 - Cytokine zalpha11 ligand: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049531 - Glp-1 agonist and cardiovascular complations: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.... Agent: Novo Nordisk, Inc. Patent Department

20070049522 - Kallikrein-inhibitor therapies: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.... Agent: Fish & Richardson PC

20070049523 - Liquid composition of modified factor vii polypeptides: The invention provides a liquid, aqueous composition, comprising (i) a modified factor VII polypeptide; (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an antioxidant; and (iv) an agent selected from the list of: a calcium salt, a magnesium salt, or... Agent: Novo Nordisk, Inc. Patent Department

20070049521 - Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof: A method of using an osteocrin (Ostn) or a NPR-C specific Ostn peptide derivative for increasing osteogenesis in a mammal comprising administering a therapeutically effective amount of said Ostn or NPR-C specific Ostn peptide derivative to the mammal.... Agent: Choate, Hall & Stewart LLP

20070049532 - Modified peptides as therapeutic agents: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by selecting a peptide that modulates the activity of a protein of interest and preparing a pharmacologic agent having... Agent: Amgen Inc.

20070049527 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049528 - Nucleic acid encoding cytokine receptor zcytor17: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049524 - Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049525 - Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation: The present invention relates ZcytoR21 antagonists, such as soluble receptors and anti-ZcytoR21 antibodies, that are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. ZcytoR21 is a receptor for IL-17C. The present invention includes... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049526 - Uses of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049533 - Psma peptide analogues: Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which... Agent: Knobbe Martens Olson & Bear LLP

20070049534 - Diaminopyrimidines as p2x3 and p2x2/3 modulators: m

20070049535 - Preventive/remedy for diabetic complications using oligopeptide: The present invention provides a novel agent for the prophylaxis or treatment of diabetic complications. Specifically, the present invention provides an agent for the prophylaxis or treatment of diabetic complications, which contains, as an active ingredient, an oligopeptide containing at least two amino acid residues having an amino group or... Agent: Cermak & Kenealy LLP Acs LLC

20070049536 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070049537 - Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture: e

20070049538 - Methods for using cucurbitacin compounds: Cucurbitacins, cucurbitacin derivatives, and methods for making and using the same are provided.... Agent: Crompton, Seager & Tufte, LLC

20070049539 - Rsk inhibitors and therapeutic uses thereof: The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present... Agent: University Of Virginia Patent Foundation

20070049542 - Antisense antibacterial method and compound: A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10... Agent: Perkins Coie LLP

20070049544 - Antisense iap nucleobase oligomers and uses thereof: The present invention features nucleobase oligomers that hybridize to IAP polynucleotide, and methods for using them to enhance apoptosis and treat proliferative disorders.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070049545 - Antisense modulation of fibroblast growth factor receptor 3 expression: Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 3. Methods of using these compounds for modulation of fibroblast growth factor receptor 3 expression and... Agent: Knobbe, Martens, Olson & Bear, LLP

20070049550 - Chimeric immunomodulatory compounds and methods of using the same - iv: The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.... Agent: Morrison & Foerster LLP

20070049541 - Method for the modulation of function of transcription factors: There is provided a method of modulating the function of a transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding site for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of a transcription factor and a pharmaceutically... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070049547 - Methods for use in modulating mir-122a: Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue... Agent: Woodcock Washburn LLP

20070049548 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049549 - Methods of treating cancer using il-21: Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a... Agent: Zymogenetics, Inc. Intellectual Property Department

20070049540 - Oligonucleotide inhibiting the expression of star-binding protein (sbp) gene and method therefor: The present invention relates to a means to inhibit the production of StAR binding protein, which binds to StAR protein, i.e. a cholesterol transport stimulating factor, and regulates the function of StAR protein; and furthermore, leads to induce apoptosis specifically in cancer cells by impairing said function. A protein, which... Agent: Drinker Biddle & Reath (dc)

20070049543 - Rna interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-hsd-1) gene expression using short interfering nucleic acid sina: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070049546 - Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals: A substituted, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, a method for the production thereof, and a vaccine containing said substituted, non-coding nucleic acid molecule. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in... Agent: Nils H. Ljungman Nils H. Ljungman & Associates

20070049551 - Method for enhancing mammalian immunological function: Low molecular weight modified pectin, particularly modified citrus pectin (MCP), and/or low molecular weight modified alginate is useful in a composition for stimulating the immune response of a mammal, particularly a human. Modified pectin and/or modified alginate is administered in a composition in an amount sufficient to modulate, support, enhance... Agent: Merchant & Gould PC

20070049552 - Fluoroquinolone formulations and methods of making and using the same: A pharmaceutical composition comprising a fluoroquinolone such as ciprofloxacin, cyclodextrin, and a hydroxy acid is described. The composition may be an aqueous composition, with such aqueous compositions preferably having a pH between 5 and 7. In some preferred embodiments, the composition further comprises a soluble polymer.... Agent: Nixon & Vanderhye, PC

20070049553 - Amino sugar chelates: The present invention includes amino sugar chelates and methods for preparing amino sugar chelates of the formula given below, where M is a metal; R2 and R3 are independently selected from H, OH and hydroxyl substituted C1-C8 alkyl; R4 is selected from H, CO2H, OH, and hydroxyl substituted C1-C8 alkyl;... Agent: Brinks Hofer Gilson & Lione Utah Office

20070049554 - Method for treatment or prevention of conditions caused by gram-positive bacteria: The treatment, prevention and prophylaxis of conditions such as sepsis, septic shock, systemic inflammatory response syndrome or “SIRS”, SIRS with organ dysfunction or failure, organ failure and organ dysfunction are described. These conditions are associated with infection by Gram-positive bacteria. The treatment involves the administration of compositions containing a phospholipid,... Agent: Fulbright & Jaworski, LLP

20070049555 - Indenoisoquinolinone analogs and methods of use thereof: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease,... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070049556 - Novel benzopyran derivatives as potassium channel openers: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20070049557 - Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone; and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070049558 - New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors: e

20070049559 - Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells: Preparations for controlling intraocular pressure in the eye comprise as an active compound, arylazine substituted with a carbonylic moiety, which compound is capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork to promote outflow of aqueous. The organic active compound increases Gelatinase A activity... Agent: Bausch & Lomb Incorporated

20070049564 - 9-aminocarbonylsubstituted derivatives of glycylcyclines: e

20070049561 - Methods of purifying tigecycline: Methods of preparing and purifying tetracyclines, such as tigecycline, are disclosed. Also disclosed are tetracycline compositions, such as tigecycline compositions, prepared by these methods.... Agent: Wyeth/finnegan Henderson, LLP

20070049562 - Tigecycline and methods of preparation: Methods of preparing and purifying tetracyclines, such as tigecycline, are disclosed. Also disclosed are tetracycline compositions, such as tigecycline compositions, prepared by these methods.... Agent: Wyeth/finnegan Henderson, LLP

20070049563 - Tigecycline and methods of preparing 9-aminominocycline: Methods of preparing and purifying tetracyclines, such as tigecycline, are disclosed. Also disclosed are tetracycline compositions, such as tigecycline compositions, prepared by these methods.... Agent: Wyeth/finnegan Henderson, LLP

20070049560 - Tigecycline and methods of preparing 9-nitrominocycline: Methods of preparing and purifying tetracyclines, such as tigecycline, are disclosed. Also disclosed are tetracycline compositions, such as tigecycline compositions, prepared by these methods.... Agent: Wyeth/finnegan Henderson, LLP

20070049565 - Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction: The present invention relates to a combination of cell necrosis inhibitor and lithium, process for the preparation of the combination, pharmaceutical formulation containing the combination and use of the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The combination of the... Agent: Seed Intellectual Property Law Group PLLC

20070049566 - Methods and compositions for inhibition of angiogenesis: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs... Agent: Jones Day

20070049568 - Control of induced elevated intraocular pressure: A variety of ocular diseases and conditions can be treated using corticosteroids or other compounds having glucocorticoid activity. A consequence of administration of such compounds is elevated intraocular pressure, which causes undesirable side-effects. The unwanted consequences of such elevated intraocular pressure may be prevented or treated through the administration of... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070049567 - Hormone replacement composition and method: Hormone compositions comprising bioidentical hormones dispersed in a lipid-based cream are provided in syringes for dispensation and self-administration by a user. The compositions, which are topically applied by the user, are percutaneously delivered to the vascular system of the user in accordance with a dosage protocol that causes a rhythmic... Agent: Michael G Petit

20070049569 - Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same: Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a thermogenic compound. Furthermore... Agent: Jones Day

20070049570 - Quinoline derivatives as phosphodiesterase inhibitors: m

20070049571 - Dipiperazinyl ketones and related analogues: Dipiperazinyl ketones and related analogues are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion... Agent: Neurogen Corporation

20070049572 - Novel agents for preventing and treating disorders involving modulation of the ryr receptors: and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated... Agent: Wilmerhale/columbia University

20070049573 - Pyrrole-derivatives as factor xa inhibitors: The present invention relates to compounds of the formulae (I) and (Ia), wherein R0; R1; R3; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae (I) and (Ia) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070049574 - New pyrazolones as 11b-hsd1 inhibitors for diabetes: e

20070049575 - Preparation of hymenialdisine derivatives and use thereof: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α). The chemically-synthesized indoloazepines of the invention also inhibit... Agent: Mcleod & Moyne, P.C.

20070049576 - Neurogenesis by muscarinic receptor modulation: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent... Agent: Townsend And Townsend And Crew, LLP

20070049577 - Cgrp antagonists: which are antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such... Agent: Louis J. Wille Bristol-myers Squibb Company

20070049578 - Cinnamamide compounds as metabotropic glutamate receptor antagonists: i

20070049580 - Anxiolytic agents with reduced sedative and ataxic effects: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.... Agent: Wisys Technology Foundation, Inc. C/o Mirick, O'connell, Demallie & Lougee, LLP

20070049579 - Medicament having neovascularization promoting action: A medicament having a neovascularization promoting action, which comprises a retinoid antagonist such as 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid as an active ingredient and is useful for prophylactic and/or therapeutic treatment of ischemic diseases and wounds.... Agent: Greenblum & Bernstein, P.L.C

20070049581 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3 and R4 are as defined in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070049582 - Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression: e

20070049583 - Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents: Compounds of formula (I), their tautomeric and isomeric forms and salts, as well as the process for their production and their use in pharmaceutical compositions, are described.... Agent: Berlex Biosciences Patent Department

20070049584 - Amino-tetrazoles analogues and methods of use: m

20070049585 - Benzamide and benzoate anti-hiv compounds: The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070049586 - 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents: Certain compounds of Formula I and Formula II disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents.... Agent: Cantor Colburn, LLP

20070049587 - Factor xa inhibitors: r

20070049588 - Atm inhibitor:

20070049589 - Indole acetic acid acyl guanidines as beta-secretase inhibitors: or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and R8 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The... Agent: Louis J. Wille Bristol-myers Squibb Company

20070049590 - Compositions comprising zopiclone derivatives and methods of making and using the same:

20070049591 - Inhibitors of mapk/erk kinase: The present invention relates to compounds useful as inhibitors of MEK kinase and methods for the treatment or prevention of cellular proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.... Agent: International Patent Group Attn: Ms Lavern Hall

20070049592 - Bis-aryl urea compounds and methods of use: wherein A1, A2, B1, B2, Q, X1, X2, Y and R3 are defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compounds and compositions are capable of modulating various protein kinase receptors such as Tie-2 and, therefore, influencing kinase related disease states and conditions. The compounds, for example,... Agent: Amgen Inc.

20070049593 - Tetracyclic fused heterocyclic compound and use thereof as hcv polymerase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory... Agent: Leydig Voit & Mayer, Ltd

20070049594 - Novel compounds and compositions as cathepsin inhibitors: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... Agent: Ross J. Oehler Aventis Pharmaceuticals Inc.

20070049595 - Novel pyridazine derivatives and medicines containing the same as effective ingredients: wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted)... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070049596 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv): The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.... Agent: Robert Deberardine Abbott Laboratories

20070049597 - P38 map kinase inhibitors and methods for using the same: wherein X and Y are nitrogen or one of X and Y is nitrogen and the other is CRg, and W, D, E, R4, R5, R6 and R9 are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds in the treatment... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070049598 - P38 map kinase inhibitors and methods for using the same: wherein X and Y are N or one of X and Y is N and the other is CRg, and A, D, E, G, W, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070049600 - Pteridinones as kinase inhibitors: R8 is (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl. These compounds are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The present invention also provides a method of treating cell proliferative disorders.... Agent: Pfizer Inc

20070049599 - Use of bh4 for the treatment of respiratory diseases: The invention describes the use of Tetrahydrobiopterin (BH4) or derivatives thereof for the treatment of COPD. In a preferred embodiment, BH4 or derivates thereof are combined with arginine or derivatives thereof.... Agent: Nath & Associates PLLC

20070049601 - Benzofuran inhibitors of factor viia: Compounds of Formula I are useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein and have improved pharmacokinetic properties. These compounds may be used in methods of preventing and/or treating clotting disorders.... Agent: Genentech, Inc.

20070049602 - selective apoptotic induction in cancer cells including activation of procaspase-3: Compounds and related methods for synthesis, and the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3, and particular embodiments are capable of direct activation of procaspase-3 and... Agent: Greenlee Winner And Sullivan P C

20070049603 - Raf inhibitor compounds and methods of use thereof: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in... Agent: Viksnins Harris & Padys Pllp

20070049604 - Piperazinylalkylpyrazole derivatives useful as selective t-type calcium channel blockers and preparation method thereof: m

20070049605 - Dibenzo chromene derivatives and their use as erbeta selective ligands:

20070049606 - Bicyclic heterocycles as hiv-integrase inhibitors: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with... Agent: Louis J. Wille Bristol-myers Squibb Company

20070049607 - Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists: or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder... Agent: Foley And Lardner LLP Suite 500

20070049608 - Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use: Disclosed are pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use.... Agent: Lexicon Genetics Incorporated

20070049610 - Diaminopyrimidines as p2x3 and p2x2/3 modulators: s

20070049609 - Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases:

20070049611 - Phosphodiesterase 4 inhibitors:

20070049612 - Bridged n-cyclic sulfonamido inhibitors of gamma secretase: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070049613 - Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists: The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation... Agent: Louis J. Wille Bristol-myers Squibb Company

20070049614 - Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject: A method of improving stool frequency in a subject having diarrhea-predominant IBS, comprising administering a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof to a subject in need of treatment in an amount sufficient to decrease stool frequency within 2 days or less of administering.... Agent: Mayer, Brown, Rowe & Maw LLP

20070049615 - Compounds and methods for development of ret modulators: Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and strucural information can, for example, be used for identifying molecular scaffolds and for developing... Agent: Foley & Lardner LLP

20070049616 - Organic compounds: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in... Agent: Novartis Corporate Intellectual Property

20070049617 - Argatroban formulation: An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.... Agent: Baxter Healthcare Corporation

20070049618 - Isoindole-imide compounds and compositions comprising and methods of using the same: This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Jones Day

20070049619 - Alpha-amino acid derivatives and use thereof as medicines: Compounds represented by the α-amino acid derivative or a pharmaceutically acceptable salt thereof of the present invention have a therapeutic effect due to a DPP-IV inhibitory action and useful as pharmaceutical agents for the treatment and/or prophylaxis of diseases relating to a DPP-IV inhibitor.... Agent: Leydig Voit & Mayer, Ltd

20070049620 - Cyclic tertiary amine compound: wherein A represents an optionally substituted trivalent group which is benzene, pyrimidine, pyrrole, pyridine, pyridazine, furan, thiopene, pyrazole, imidazole, isoxazole or isothiazole; R1 represents an aryl or a heteroaryl group, which is unsubstituted or substituted; R2 represents a heteroaryl group which is unsubtituted or substituted; and R3 represents a cyclic... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070049621 - 6-alkylamino-2-methyl-2'-(n-methyl substituted sulfonamido)methyl-2h-1-benzopyran derivative as anti-inflammatory inhibitor: The present invention relates to a noble 6-alkylamino-2-methyl-2′-(N-methyl substituted sulfonamido)methyl-2H-1-benzopyran derivative, a method for preparing the same with high efficiency using a parallel synthetic method, one of combinatorial chemical synthetic techniques, and a use of the novel compound showing a high inhibitory effect to 5-lipoxygenase (5-LO) activity for preventing and... Agent: Frommer Lawrence & Haug

20070049622 - Substituted benzimidazoles and methods of preparation: Methods for preparing new substituted benzimidazole compounds having formula (I) useful for treating kinase mediated disorders are provided wherein R1, R2, R3, R4, a, b, and c are defined herein... Agent: Novartis Vaccines And Diagnostics Inc.

20070049623 - Imidazolidinone compounds: t

20070049624 - Derivatives of pyridone and the use of them: The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070049625 - Ep2 receptor agonists for treating glaucoma: e

20070049626 - Treating premature ejaculation using gabapentin and pregabalin prodrugs: Disclosed herein are methods of using prodrugs of gabapentin and pregabalin, and pharmaceutical compositions thereof, to treat premature ejaculation in male humans, and pharmaceutical compositions of prodrugs of gabapentin and pregabalin useful in treating premature ejaculation.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070049627 - Treating vulvodynia using prodrugs of gaba analogs: Methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat vulvodynia in a patient, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating vulvodynia are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070049628 - Benzoxazole inhibitors of 15-lipoxygenase: The present application provides benzoxazole inhibitors of 15-LO, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070049629 - Non-steroidal antiandrogens: The invention provides non-steroidal ligands for the androgen receptor, methods for making non-steroidal ligands of the androgen receptor, compositions of non-steroidal ligands of the androgen receptor and methods of using non-steroidal ligands and compositions of non-steroidal ligands of the androgen receptor for treating or preventing diseases (e.g., prostate cancer) associated... Agent: Fish & Richardson P.C.

20070049630 - Method of using ryanodine receptor antagonists to treat amyotrophic lateral sclerosis: The present invention provides a method of providing neural protection in in human patients suffering from amyotrophic lateral sclerosis comprising administering to said patients suffering from said amyotrophic lateral sclerosis an effective amount of a compound that is a ryanodine receptor antagonist in pharmaceutically acceptable vehicle to inhibit or prevent... Agent: Robert J. Baran (t2-7h) Allergan, Inc.

20070049631 - Ectoparasiticidal formulations of spinosyms and azole pesticides: The present invention relates to formulations comprising a combination of an azole pesticide and spinosyns as active ingredients for the control of ectoparasites, a method for making a medicament for controlling an ectoparasite infestation by simultaneously or sequentially administering the active ingredients in combination, and a method for controlling an... Agent: Intervet Inc. Patent Department

20070049632 - Pyrazolones as inhibitors of 11b-hydroxysteroid dehydrogenase: e

20070049633 - P38 map kinase inhibitors and methods for using the same:

20070049634 - Microcrystals and pharmaceutical formulations comprising the same:

20070049635 - Diamine derivatives, process for producing the same, and plant disease control agents containing the same as active ingredients: [In Formula, R1 represents, for example, a halogenated hydrocarbon having the carbon number of 1 to 6; R2 and R7 independently represent, for example, a hydrogen atom or a hydrocarbon having the carbon number of 1 to 6; R3 and R4 independently represent, for example, a hydrogen atom or a... Agent: Buchanan, Ingersoll & Rooney PC

20070049636 - Pharmaceutical compositions: The present invention relates to a pharmaceutical composition comprising primarily amorphous 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.... Agent: Robert Deberardine Abbott Laboratories

20070049637 - Process for the synthesis of cationic lipids: e

20070049638 - Polymorphic forms of 3-amino-1-propanesulfonic acid: Polymorphic forms of 3-amino-1-propanesulfonic acid are described.... Agent: Lahive & Cockfield, LLP

20070049639 - Aspirin-triggered lipid mediators: Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070049640 - Acetylcysteine composition and uses therefor: This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070049641 - Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis: The present invention relates to pharmaceutical kits and methods to treat lung inflammation and redox imbalance in human cystic fibrosis patients using pharmaceutical compositions containing N-acetylcysteine (NAC), pharmaceutically acceptable salts of N-acetylcysteine, or N-acetylcysteine derivatives. In phase I studies, treatment with oral NAC at a dose of from about 1800... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070049642 - Method and apparatus for producing synergistic biocide: An apparatus and methods to produce synergistic mixtures (or combinations) of haloamines to control growth of microorganisms in aqueous systems are disclosed. The apparatus and methods to produce synergistic mixtures entails producing a batch quantity of a haloamine and converting part of the haloamine to a second haloamine species to... Agent: Hercules Incorporated Hercules Plaza

20070049643 - Hydroxylamine derivatives: This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a... Agent: Young & Thompson

20070049644 - Spatial inhibitors, deterrents and repellents for mosquitoes and midges: Certain components of citrus fruits and oxidation products of limonene are effective deterrents, repellents and/or spatial inhibitors for mosquitoes and biting midges. The compounds that have been found to be deterrents, repellents and infibitors for mosquitoes and biting midges are neryl acetate, citronellyl acetate, geranyl acetate, hydroxy-p-cymene, citral, α-terpineol, citronellal,... Agent: George W. Rauchfuss, Jr. Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070049645 - Anti-nausea and anti-vomiting activity of cannabidiol compounds: The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.... Agent: Wolf Greenfield & Sacks, PC